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Proteins mediate important biological processes by interacting with other 
biomolecules, namely, other proteins, peptides, sugars, lipids or nucleic acids. 
This thesis presents my works on protein-peptide interactions using 
computational approaches. The thesis is focused on a specific peptide 
conformation, namely the polyproline type II helix (PPII). The protein-PPII 
interactions are crucial to several processes such as signaling pathways, 
localization, immune response, post-translational modifications etc.  
Three different aspects of protein-PPII interactions have been studied to 
decipher the specificity of these interactions. First, two X-ray crystal structures 
of major histocompatibility complex class II (MHCII) in the complexes with 
two peptides having PPII conformation have been refined. Based on the 
crystal structures and molecular dynamics (MD) simulations, the reasons why 
certain peptides are retained in that MHCII has been revealed. Next, MD 
simulations on MHCII-peptide complexes have been performed to understand 
the peptide editing mechanism by a catalyst, DM. The study showed that DM 
can stabilize the peptide-free MHCII by the interaction not only at α1 and β1 
domains, but also at β2 domain. Third, we have also analyzed the protein-PPII 
interaction by studying PPII receptor proteins. The analysis suggests specific 
features for PPII-binding. These features have been used to predict the PPII-
receptor propensity of a query protein.  
As electrostatics play an important role in mediating these interactions, we 
have studied the protonation states of ionizable residues, pKa, in proteins. This 





all protein structures. Our pKa prediction protocol is a simple and relatively 
accurate method. The accuracy is within a fraction of a pH unit. 
This thesis presents the intensive studies on different aspects of protein-PPII 
interactions and could contribute to the knowledge of these interactions as well 
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Chapter 1  
Introduction 
1.1 Introduction to Protein-Peptide Interactions 
At the cellular level living organisms use protein to perform their essential 
biological functions, such as signaling network, DNA repair, metabolism, gene 
expression, replication, transporting and folding. These functions are 
performed when proteins interact with other molecules, such as other proteins, 
peptides, sugars, lipids or nucleic acids. Among these interactions, the most 
abundant are protein-protein interactions, 15 to 40% of which is mediated by a 
stretch of a small peptide
1
. The protein-peptide interactions involve in 
signaling, regulatory networks, cell localization, protein degradation, and 
immune response. Recently, it was shown that protein-peptide interactions 




Many experimental methods could be used for identifying protein-peptide 
interactions at the atomic resolution. The common techniques include but are 
not limited to X-ray crystallography
3
, nuclear magnetic resonance (NMR) 
spectroscopy
4
, alanine scanning mutagenesis
5
 and mass spectrometry
6
 
approaches. These techniques are valuable and have contributed to the 
knowledge of protein-peptide interactions. However, these techniques have 
many drawbacks like difficulties in expression and purification of large 
proteins, obtaining high resolution X-ray structures or restriction of the protein 





consuming and labor intensive. Over the last 30 years, computational 
approaches for identifying the protein-peptide interactions have been 
developed. However, those approaches are still in the infant stage, despite the 
availability of more than 100, 000 protein structures in the protein data bank 
(PDB). The reason for this drawback could be due to insufficiency of protein-
peptide interaction types, or the lack of knowledge in the features that 
contribute to the protein-peptide interactions. And hence, there are still open 
questions about protein-peptide interactions; such as: Are there common 
principles for peptide binding in different cellular functions? What factors help 
to stabilize protein-peptide interactions? Are such factors common in certain 
structural or functional families? Are there special conformations on the 
protein for recognizing the binding peptide? Is it possible to predict and/or 
design peptides that would have high affinity to the binding pocket of a 
particular protein? To address these questions, it is necessary to first 
categorize and gain insight from structural data on existing protein-peptide 
complexes. As more than one third of the protein-binding peptides have 
extended beta or polyproline II (PPII) helical conformation
7
, this thesis 
focuses only on protein-PPII interactions. 
1.2 Thesis Organization  
In this thesis, the following issues have been tackled: 
(1) In-depth learning on an example of the protein-peptide complex involved 
in the immune pathway, where the peptide has PPII conformation. This is a 





the complex structures with the follow up of analyzing the structures using 
molecular dynamics (MD) simulations; 
(2) Conformational study on the PPII-peptide editing process of MHCII by a 
catalyst. This is an MD simulation study on different complex systems to 
understand this particular protein-PPII interaction. 
(3) Predicting PPII-binding propensity of a protein. The target protein was 
aligned with a template of two residues from known PPII-binding proteins. All 
the possible alignments were then classified as the binding or nonbinding 
positions by support vector machine (SVM). The PPII peptide from the 
template structure was then used to build into the target structure using Monte 
Carlo simulations. We also applied this model to find the new PPII receptors 
in a non-redundant dataset of 30% sequence identity from PDB; 
(4) As charges of ionizable residues play a critical role in protein functions and 
protein-peptide interactions, we have exploited the prediction protocol for 
identifying the charge or protonation state of these ionizable residues; 






Chapter 2  
Structural Basis of  
HLA-DQ2.5‒CLIP Complexes 
In this chapter, an example of protein-peptide interaction, particularly DQ2.5-
CLIP complex, was studied. This complex structure correlates with a 
particular disease. Understanding the interaction in this complex could give 
insight into the disease mechanism. 
2.1 Background and Motivations 
Antigenic peptides are presented to T cell receptors of CD4 T cells
8
 by MHCII 
proteins. These proteins have a peptide binding groove formed by one α chain 
and one β chain. Only three MHCII isotypes, namely DR, DP and DQ, are 
found in human. All these isotypes are encoded on chromosome 6. MHCII 
proteins are synthesized in the endoplasmic reticulum in a nanomeric complex 
with a chaperone protein called the invariant chain (Ii) or α3β3Ii3
9
. By the 
formation of this complex nascent MHCII is prevented from interacting with 
indiscriminate peptides and the MHCII-Ii complex is targeted to the endosome 
where MHC performs its function
10
. Once in the endosome, the invariant chain 
from MHCII-Ii complex is progressively proteolyzed until only a short 
fragment called class-II-associated invariant chain peptide (CLIP) remains in 
the peptide binding groove of the MHCII
11
 (αβ). Subsequently, with the help 
of a catalyst, DM, CLIP is released and replaced by exogenous peptides. The 





. DM acts as a catalyst to edit either CLIP or low 
binding affinity peptides
12-14





MHCII were detected. They are the canonical CLIP1 (residues 83-101), non-
canonical CLIP2 (residues 92-107), and non-canonical CLIP3 (residues 98-
111) (Figure 2.1). Among the three regions, CLIP1 is exclusively observed in 
most mouse and human MHCII proteins
12
. So far the only proteins, which are 
shown to bind both CLIP1 and CLIP2 peptides, are DQ2.2, DQ2.5, DQ7.5, 
and DQ8
15-17
. DQ7.5 also binds CLIP3
17
. Interestingly, those human MHCII 
alleles binding to CLIP2 and CLIP3 are associated with one or more 
autoimmune diseases; particularly celiac disease (DQ2.2, DQ2.5, DQ7.5 and 
DQ8)
18-20




Figure 2.1: Sequence and homo-trimer forms of human invariant chain. (a) 
Amino acid sequence. MHC binding core sequence of CLIP1 is 
MRMATPLLM and that of CLIP2 is PLLMQALPM. MHC binding core 
sequence of CLIP3 is unknown. (b) Solution NMR structure of the truncated 
human invariant chain protein (residues 118-192, PDB ID: 1IIE). The 
invariant chain exists as a homo-trimer and associates with three major 
histocompatibility complex proteins simultaneously in the endoplasmic 
reticulum. 
DQ2.5 allele is associated with an autoimmune-like disorder, celiac disease, 
caused by a harmful immune response when wheat gluten and similar proteins 
from rye and barley
21
 are ingested. About 95% of celiac disease patients 
express DQ2.5. This allele is encoded by the DQA1*05:01 and DQB1*02:01 
genes of the DR3‒DQ2 haplotype18. The gluten-specific CD4+ T cells of celiac 
disease patients recognize a various set of gluten epitopes when they are 







. DQ2.5 has unusually high CLIP phenotype. Up to 53% 
of exogenous displayed peptides
15-17,26
 in DQ2.5 expressing B lymphoblastoid 
cells are CLIP peptides, either CLIP1 or CLIP2. While in general, only 10% of 
displayed peptides in other MHCII are CLIP
27
. Moreover, in DQ2.5 the 
amount of the non-canonical CLIP2 peptide is higher than that amount of the 
canonical CLIP1
15,16
. The CLIP-rich phenotype in DQ2.5 was explained by 
the poor interaction between DQ2.5 and DM
16,28
. The structural explanation 
for the unusual CLIP amount is not clear at the atomic level. Here, we have 
determined the crystal structures of DQ2.5–CLIP1 and DQ2.5–CLIP2 to have 
insight into the DQ2.5–CLIP interaction. 
2.2 Methods and Experimental Procedures 
2.2.1 Expression and Purification 
The preparation of DQ2.5 containing covalently linked CLIP1 and CLIP2 is 
similar to DQ2.5–αI gliadin22,29-31. The Fos and Jun leucine zippers were 
attached to the C-termini of the α- and β-chains, respectively, through an 
intervening Factor Xa site to promote heterodimer stability
31,32
. A 15-residue 
linker was used to attach the CLIP1 (PVSKMRMATPLLMQA) and CLIP2 
(MATPLLMQALPMGAL) peptides to the N terminus of the β-chain. A 
baculovirus expression system was used to coexpress the α- and β-chains in 
ExpresSF+ insect cells. The DQ2.5 heterodimer was purified using mAb 2.12. 
E11
29
, concentrated, and washed using a size exclusion filter. The MD 





systems to understand the mechanism of how CLIP is retained in DQ2.5 and 
how DM is less susceptible to DQ2.5. 
2.2.2 Crystallization and Data Collection 
Factor Xa was used to remove the leucine zippers from the DQ2.5–CLIP1 and 
DQ2.5–CLIP2 complexes for 16 hours at 24ºC. Purification of both complexes 
was conducted using anion exchange (buffer A: 25 mM Tris, pH 8.0, buffer B: 
25 mM Tris, pH 8.0, 0.5 M NaCl) and size exclusion chromatography (buffer: 
25 mM Tris, pH 8.0). The solution was then concentrated to 2 mg/ml. Both 
complexes were crystallized by combining 1 µl of the protein solution and 1 µl 
of respective precipitant buffer in a single hanging drop at 18 ºC. The buffer 
used for DQ2.5–CLIP1 was 0.1 M ammonium sulphate, 0.1 M sodium 
cacodylate, pH 6.5, 25% PEG 8000 and 6% glycerol, while for DQ2.5–CLIP2, 
the buffer was 0.1 M BIS-TRIS, pH 5.5, 22% PEG 3350. Small crystals of 
both DQ2.5–CLIP1 and DQ2.5–CLIP2 complexes appeared within one week 
and then grew to its full size in two weeks. Crystals were soaked in 5% 
glycerol + mother liquor and later flash frozen in liquid nitrogen. X-ray 
diffraction data were collected at the Stanford Synchrotron Radiation 
Laboratory at the beam line 9-3. HKL2000 program was used to index and 
integrate the diffraction data
33
. DQ2.5–CLIP1 crystal has the C121 space 
group. Its cell dimensions are a=128.86 Å, b=69.21 Å, c=146.69 Å and β = 







2.2.3 Structure Determination and Analysis 
Molecular replacement using Phaser
34,35
 was used to determine both 
structures. The search model was DQ2.5–gliadin structure (PDB ID: 1S9V). 







CLIP1 and CLIP2 peptides were built at the end of the refinement process, 
using the Fo-Fc electron density map at 3.0 ζ. Throughout the refinement 
isotropic B correction and bulk solvent correction were applied. Water 
molecules were identified in the 2Fo–Fc map from electron density map greater 
than 1.0 ζ. All the water molecules were checked for environment, valid 
geometry, and density shape before conducting additional model building and 
refinement cycles. The last two refinement rounds included TLS (translation, 
libration, and screw–rotation displacements) parameterization. PROCHECK38 
was used for checking the stereochemical quality of the final structures. 
2.2.4 Model Building of DQ2.5 (Wild Type)–CLIP1–DM and 
DQ2.5 (Eβ86G, Qα31I, Hα24F)–CLIP1–DM  
Both the wild type and mutant DQ2.5–CLIP1–DM complexes were modeled 
using the MODELLER program version 9.1039,40. The templates were the 
crystal structure of DR1–HA–DM (PDB code: 4FQX) and DQ2.5–CLIP1 
(PDB code: 5KSU). In this model, CLIP1 was truncated to the same length 
(from P2 to P10) as the HA peptide in the DR1–HA–DM crystal structure. 
Total of five models evaluated by the DOPE statistical energy function41 were 
created. Energy minimized models were achieved by slow refine option. All 





2.2.5 Molecular Dynamics Simulations 
Introduction to MD simulations is on chapter 3.2. All-atom MD simulations 
were carried out on three systems, including, DQ2.5(wild type)–CLIP1, 
DQ2.5(wild type)–CLIP1–DM and DQ2.5(Eβ86G, Qα31I, Hα24F)–CLIP1–
DM. All crystal water molecules were included in the starting MD structures 
because they are important for mediating the protein–peptide interactions44-46. 
The protonation states of all ionizable residues, including ASP, GLU, HIS, 
LYS and ARG were assigned according to the model pKa at pH equal to 7. 
TIP3P water box with the minimum distance of 12 Å to any protein atom was 
used to solvate each system (Table 2.1). Sodium counter ions were used to 
neutralize the systems. Periodic boundary conditions were applied on the 
system.  









DQ2.5–CLIP1 P-4(14) -6 21437 
DQ–CLIP–DM P2 (9) -24 30139 
DQ (mutant)–CLIP–DM P2 (9) -24 29243 
 
First energy minimization using the steepest descent and then the conjugate 
gradient methods was applied to the complex. The system was heated to 300K 
within 800 ps under the NVT conditions. The system was then equilibrated for 
1 ns under the NPT conditions. Later, under the NVE conditions the triplicate 
MD simulations were carried out for 50 ns. 





were carried out using the ff99SB47 force fields in the AMBER12 program48. 
The long-range interactions were calculated by the Particle Mesh Ewald 
(PME)49 algorithm while the cutoff of 10.0 Å was applied for the short-range 
interactions. The integration time step was set to 1 fs. The analysis on MD 
trajectories was carried out using a combination of indigenously developed 
Python scripts and the Ptraj/Cpptraj module of Amber12. 
2.2.6 Cavity Calculation 
The Voronoi algorithm
50
 was applied to calculate the cavity of the P4 pocket 
in MHCII. 
2.3 X-ray Crystal Structure Analysis  
2.3.1 Crystal Structures of DQ2.5–CLIP1 and DQ2.5–CLIP2 
The crystal structures of DQ2.5–CLIP1 and DQ2.5–CLIP2 complexes were 
solved to 2.73 Å and 2.20 Å resolutions, respectively (Figure 2.2). Both 
structures do not have density for the β105-112 loop. Side chain atoms of 
α75K, α158E, α172K, β22E and β135D residues in the DQ2.5–CLIP1 
structure could not be placed. Data collection and refinement statistics are 
presented in Table 2.2. The DQ2.5 conformation in the DQ2.5–CLIP1 
structure is similar to that conformation in the DQ2.5–CLIP2, the DQ2.5–





 RMSD of 360 atoms ranging from 0.57 to 
1.27 Å). The CLIP1 and CLIP2 peptides in the current structures have highly 
similar main chain (C
α







RMSD of 0.85 Å).  
Table 2.2: Data collection and refinement statistics  
Complex name DQ2.5–CLIP 1 DQ2.5–CLIP 2 
PDB code 5KSU 5KSV 
Data collection   
Space group C121 I23 
Cell dimension   
a, b, c (Å) 128.86, 69.21, 146.69 137.01, 137.01, 137.01 
α, β, γ (°) 90, 110.3, 90 90, 90, 90 
Resolution (Å) 2.73 (2.80-2.73) 2.20 (2.30-2.20) 
Rmerge (%) 10.0 12.9 
I/ζI 11.7 12.7 
Completeness (%) 93.7 (89.2) 99.7 (99.9) 
Redundancy 3.5 6.5 
Refinement   
Resolution (Å) 39.26-2.73 36.62-2.20 
 (2.80-2.73) (2.30-2.20) 
Number of reflections 29676 21938 
Rwork / Rfree 0.187/0.247 0.171/0.208 
 (0.29-0.37) (0.231-0.296) 
Number of atoms 6144 3176 
Protein 6027 3003 
Water 117 173 
B-factors (Å
2
) 45.0 28.1 
Protein 45.1 28.1 
Water 35.9 29.0 





Bond length (Å) 0.01 0.01 





Values for highest resolution shell are in parentheses. 
 
 
Figure 2.2: Crystal structures of CLIP1/CLIP2 peptides bound to DQ2.5. (a) 
Crystal structure of DQ2.5–CLIP1 (PDB ID: 5KSU). (b) Crystal structure of 
DQ2.5–CLIP2 (PDB ID: 5KSV). DQ2.5 α- and β-chains are in blue and pink, 
respectively. CLIP1 and CLIP2 peptides are shown in stick representation 
(light yellow, carbon; dark yellow, sulfur; blue, nitrogen; red, oxygen). 
Hydrogen bond interactions are represented in red dotted lines. 
In the DQ2.5–CLIP1 structure, 14 residues of CLIP1 are clearly visible in the 
electron density map (Figure 2.3a). Residues MRMATPLLM in CLIP1 
peptide (Ii 91-99) occupy the P1–P9 pockets of DQ2.5. This binding register is 
seen in all MHCII–CLIP1 crystal structures solved to date: DR1–CLIP1 (PDB 







. In the DQ2.5–CLIP2 structure, 12 residues of CLIP2 are clearly 
visible in the electron density map (Figure 2.3b). Residues PLLMQALPM in 
CLIP2 peptide (Ii 96-104) occupy the P1–P9 pockets of DQ2.5. This 





Figure 2.3: 2Fo-Fc electron density maps of CLIP peptides with a contour of 
1.0ζ. (a) CLIP1 and (b) CLIP2 peptides. CLIP1 and CLIP2 peptides are shown 
in stick representation (light yellow, carbon; dark yellow, sulfur; blue, 
nitrogen; red, oxygen). 
CLIP1 has 12 direct and four water-mediated hydrogen bonds with DQ2.5, 
while CLIP2 has 14 direct and six water-mediated hydrogen bonds with 
DQ2.5 (Figure 2.2). There are two hydrogen bond interactions which are 
present in DQ2.5–CLIP1 but absent in DQ2.5–CLIP2; particularly (     
     , and     
  
      ). The first interaction is not possible in DQ2.5–
CLIP2 because the P1 residue in CLIP2 is a Pro, where the backbone nitrogen 
is in cyclic conformation and lacks the ability to make hydrogen bond 
interactions with backbone oxygen. There are three hydrogen bond 
interactions that are present in DQ2.5–CLIP2 but missing in DQ2.5–CLIP1 
(          
  
,    
        
  
,          





possible in DQ2.5–CLIP1 because the main chain carbonyl C=O group of 
CLIP1 P-3 is rotated away from DQ2.5 β88, and because the P5 and P6 
residues of CLIP1 are different from those of CLIP2. Overall, the DQ2.5 
binding energy for CLIP1 and CLIP2 appear to be similar. This similarity was 
indicated by the experimentally measured dissociation time for DQ2.5–CLIP1 
(140 hours) and DQ2.5–CLIP2 (140 hours) in the absence of DM16. 
Table 2.3: Binding inhibitory capacity of CLIP1 and CLIP2 peptides to 
different MHCII proteins 
MHCII *IC50 (nM) Reference 
 
**
CLIP1 CLIP2  



















































Sette et al. and Vartdal et al. used different indicator peptides for IC50 
measurement. 
** 
Human CLIP1 used by Sette et al. is Ii 80-103 (sequence: 
LPKPPKPVSKMRMATPLLMGALPM) and human CLIP1 used by Vartdal 
et al. is Ii 83-101. Mouse CLIP1 Is Ii 85-101 (sequence: 






2.3.2 Reason for the CLIP2 preference over the CLIP1 in 
DQ2.5 based on the crystal structures 
Four MHCII–CLIP1 crystal structures have been reported to date: DQ2.5–




b–CLIP1 (PDB ID: 1MUJ)53. Among these four MHCII 
proteins, only DQ2.5 has been observed to bind CLIP2
15,16
. This specific 
binding to CLIP2 in DQ2.5 could be explained by its two structural features. 
Firstly, the P4 pocket in DQ2.5 is deeper and broader than that of DR1, DR3 
and I-A
b
 because of the polymorphism at β13, β26 and β78 residues (Figure 
2.4). Particularly, cavity size of P4 pocket in DQ2.5 is 566Å
3
, that cavity from 
other three MHCII proteins ranges from 364 to 417 Å
3
. In DQ2.5 the P4 
pocket residues are β13G, β26L, and β78V. In DR1 they are β13F, β26L, and 
β78Y. In DR3 they are β13S, β26Y, and β78Y. In I-Ab they are β13G, β26Y, 
and β78V. Therefore, CLIP1, which has Ala at P4, binds to all four MHCII 
proteins whereas CLIP2, which has Met at P4, only binds to DQ2.5. Secondly, 
the DQ2.5 peptide binding groove has a positively charged (due to β70R, 
β71K and β77R), whereas in DR1, DR3, and I-Ab the grooves have a negative 
charge (due to β57D, β66D, α55E in DR1/DR3 and β57D, β66E, α55D in I-
A
b
) (Figure 2.5). CLIP1 peptide is positively charged (due to P-1 Lys and P2 
Arg) while CLIP2 does not contain any charged amino acid residues. The 
long-range electrostatic interactions are crucial in the initial formation of the 
protein–protein complexes54-58, and hence DQ2.5 is expected to interact more 
favorably with CLIP2 than with CLIP1. Indeed, it was shown by previous 
biochemical studies that CLIP2 binds to DQ2.5 with higher affinity than 
CLIP1 (IC50 of 6.0 µM vs. 82.5 µM)
26,59





three-dimensional structure of MHCII proteins, DQ8 is the only other MHCII 
which interacts with CLIP2 and, consistently, DQ8 has a large P4 pocket and a 
positively charged peptide binding groove similar to DQ2.5 (Figure 2.5).  
 
Figure 2.4: Close up of the P4 pocket in four MHCII-CLIP1 complexes. (a) 
DQ2.5‒CLIP1 (PDB ID: 5KSU), (b) DR1‒CLIP1 (PDB ID: 3PDO), (c) DR3‒
CLIP1 (PDB ID: 1A6A), and (d) I-A
b‒CLIP1 (PDB ID: 1MUJ). The MHCII 
surface for α-chain and β-chain are shown in blue and pink, respectively. β-
chain residues that line the P4 pocket are shown in stick representation. CLIP1 
peptide is shown in yellow. 
2.3.3 The CLIP-rich Phenotype of DQ2.5 by Structural Basis 
While DQ2.5 expressing cells have an unusually high CLIP phenotype (up to 
53%; CLIP1 and CLIP2 combined)
15-17,26
, peptide content of other MHCIIs 
typically has only around 10% of CLIP peptide
20
. One possible explanation is 
that DQ2.5 binds CLIP with higher affinity compared to other MHCIIs. 





 respectively (Table 2). These data do not support this 
notion. In addition, number of direct hydrogen bonds formed between CLIP1 
(P-1 to P9 only) and DQ2.5, DR1, DR3, and I-A
b
 are 11, 13, 17 and 13 
respectively. And hence, we propose that the CLIP-rich phenotype in DQ2.5 is 
due to an impaired interaction between DQ2.5 and the catalyst DM, whose 
function is to exchange CLIP peptide to higher binding affinity peptides. 
Much of the current structural and mechanistic understanding of MHCII–DM 







. Therefore, we investigated whether DQ2.5 has all the structural 
elements that facilitate the DM interaction as observing in the DR1–DM 
structure. To do this, a homology model of DQ2.5–CLIP1–DM was built 
(Figure 2.6). First, the electrostatic complementary of the contact surface areas 
between DQ2.5 and DM was examined. According to our model, DQ2.5 has 
two regions making direct contact with DM. The first region is located 
adjacent to the P1 pocket in the α1 domain and the second region is located 
near the transmembrane segment in the β2 domain. The surface charge 
distribution of these contact regions in DQ2.5 has more electrostatic 
complementarity to the corresponding surfaces of DM than DR. Therefore, the 
surface electrostatic charge distribution could be ruled out as the source of 







Figure 2.5: Adaptive Poisson Boltzmann Solver (APBS)-generated 
electrostatic surface of MHC class II proteins at pH 7.0. The negative, 
positive, and neutral electrostatics are in red, blue and white, respectively. The 
view is the top view of the peptide binding groove. (a) DQ2.5‒CLIP1 (PDB 
ID: 5KSU), (b) DR1‒CLIP1 (PDB ID: 3PDO), (c) DR3‒CLIP1 (PDB ID: 
1A6A), (d) I-A
b‒CLIP1 (PDB ID: 1MUJ), (e) DR2w2a‒Epstein Barr Virus 
DNA polymerase peptide (PDB ID: 1H15), (f) DR4w4‒human collagen II 
peptide (PDB ID: 2SEB), (g) DR52a‒integrin beta 3 peptide (PDB ID: 
2Q6W), (h) DQ8‒deamidated gluten peptide (PDB ID: 2NNA), (i) I-Ad‒
influenza hemagglutinin peptide (PDB ID: 2IAD), (j) I-A
g‒hel 11-27 peptide 
(PDB ID: 3MBE), (k) I-A
k‒conalbumin peptide (PDB ID: 1D9K), and (l) I-
E
k‒MCC peptide (PDB ID: 3QIU). The peptides bound to MHCII were 
omitted in the APBS electrostatics calculations. 
 
Figure 2.6: APBS-generated electrostatics surface of MHC class II proteins at 
pH 5.5. The negative, positive, and neutral electrostatics are shown in red, blue 
and white, respectively. (a) DQ2.5 in DQ2.5‒CLIP1 (PDB ID: 5KSU), (b) 
DR1 in DR1‒HA‒DM (PDB ID: 4FQX) and (c) DM in DR1‒HA‒DM (PDB 






Figure 2.7: Conformation of the peptide binding groove in MHCII-peptide 
complexes. (a) DQ2.5–CLIP1 (PDB ID: 5KSU), (b) DR1–CLIP1 (PDB ID: 
3PDO) and (c) DR1–HA–DM (PDB ID: 4FQX). The MHCII α- and β-chains 
are in blue and pink, respectively. Peptide bound to the MHCII is not shown. 
Next, we examined whether DQ2.5 is able to undergo the same set of 
conformational changes that DR1 undergoes upon DM binding. The α51F in 
DR1 has been identified as a key DM binding residue
61,62
. When binding to 
DM, the α51-55 loop of DR1 transforms into an α-helix, this transformation 
results in the 13Å movement of α51F side chain from its initial solvent 
exposed position to the P1 pocket cavity. In the new location α51F forms a 
hydrophobic cluster with α24F, α31I, α32F, α48F, and β89F residues (Figure 
2.7)
60
. This hydrophobic interaction is thought to stabilize the P1 pocket when 
P1 residue of the peptide is removed. In comparison with DR, DQ2.5 has a 
deletion mutation at α53. The insertion of Gly at this position results in partial 
restoring DM sensitivity in DQ2.5
63. The deletion at α53 in DQ2.5 results in 
the α51F inaccessibility by DM. The relative conformational change in α51F 
may compromise the DQ2.5–DM interaction. Further, we suggest that the DM 
insensitivity of DQ2.5 is due to the presence of an extensive hydrogen bond 
network (involving α9Y, α22Y, α24H, α31Q, β86E, β90T, and a buried water 
molecule). This hydrogen bond network spans from the P1 to the P4 pockets 
of DQ2.5 (Figure 2.8). To assess the stability of this hydrogen bond network, a 





trajectories show that all hydrogen bonds in this network, with the exception 
of the peripheral β86E Oε1‒β90T Oγ1, are stable (Figure 2.9). Furthermore, 
during the course of the DQ2.5–CLIP1–DM MD simulations we observed that 
α51F does not enter the P1 pocket likely due to the presence of the α9–α22–
α24–α31–β86–β90 hydrogen bond network. In particular, the P1 pocket is 
directly blocked by a water molecule mediated hydrogen bond interaction 
between α24H and α31Q (Figure 2.10). To examine the effect of the extended 
hydrogen bond network, we mutated the α24, α31, and β86 residues in our 
DQ2.5–CLIP1–DM model to their counterparts in DR1; particularly Eβ86G, 
Qα31I and Hα24F. Due to the ability to disrupt the α9–α22–α24–α31–β86–
β90 hydrogen bond network, these mutations are expected to restore DM 
sensitivity in DQ2.5. Our 50 ns MD simulations of the triple mutant DQ2.5 
shows that α51F does indeed occupy the P1 pocket, as seen in the DR1–HA–
DM crystal structure (Figure 2.11). In DR1, DM binding also causes a change 
from an α-helix to a loop at the β85–90 region. This conformational change 
causes a 4.7 Å movement of β89F from the protein surface to the hydrophobic 
cluster of P1 pocket floor including α51F60 (Figure 2.7). The similar 
rearrangement of the β85–90 region in DQ2.5 does not appear feasible 
because β86E and β90T residues are held in place by the extended α9–α22–
α24–α31–β86–β90 hydrogen bond network (Figure 2.8a). In summary, the α9–
α22–α24–α31–β86–β90 hydrogen bond network in DQ2.5 prevents 






Figure 2.8: Hydrogen bond network at the bottom of the peptide binding 
groove in MHCII proteins. (a) DQ2.5‒CLIP1 (PDB ID: 5KSU), (b) DR1‒
CLIP1 (PDB ID: 3PDO), (c) DR3‒CLIP1 (PDB ID: 1A6A), and (d) I-Ab‒
CLIP1 (PDB ID: 1MUJ). MHCII α- and β-chains are shown in blue and pink, 
respectively. MHC bound peptides are represented in a stick model (light 
yellow, carbon; dark yellow, sulfur; blue, nitrogen; red, oxygen). Hydrogen 
bonds are shown as red dotted lines and their distances are given in Å. Water 
molecule is shown as a red sphere. 
  
Figure 2.9: Hydrogen bond interactions of the DQ2.5–CLIP1 complex during 
50 ns MD simulations. (Left) Distance trajectories of several atom pairs in the 
α22–α24–α31–β86–β90–α9 hydrogen bond network are shown; Oε2 of β86E 
and O
γ1
 of β90T (green), Oε1 of β86E and Oε1 of α31Q (cyan), Oε1 of β86E and 
O
ε
 of α9Y (blue), Oε1 of α31Q and water (red), Nδ1 of α24H and water (violet), 
and N
ε2
 of α24H and Oε of α22Y (yellow). The threshold at 3.5Å for hydrogen 
bond distance is in black horizontal line. (Right) The color codes and distances 






2.3.4 Hydrogen Bond Interaction between the P1 Backbone 
Nitrogen of CLIP1 and the α52 Backbone Oxygen of DQ2.5 
All crystal structures of MHCII–peptide complexes have a hydrogen bond 
between the amide nitrogen of the P1 residue and the main chain carbonyl 
group of MHCII α53 if the P1 residue of the peptide is not Pro. Interestingly, 
DQ2.5 has a deletion at α53, and is able to bind gluten peptides that frequently 
have Pro at P1. That is why it was suggested that DQ2.5 is unable to form 
backbone α53-P1 hydrogen bond63. The significance of this peptide main 
chain hydrogen bond has been assessed by comparing binding of peptides 
being N-methylated at the P1 position with unmodified peptides. Such 
substitution gave decreased affinity for peptide binding to DR1 but no effect 
was seen for DQ2.5
64,65
. Interestingly, our DQ2.5–CLIP1 structure shows that 
there is indeed a hydrogen bond between the P1 main chain nitrogen of CLIP1 
and the α52 carbonyl group of DQ2.5.  
 
Figure 2.10: The occupancy of P1 pocket in different complexes. (a) DQ2.5–
CLIP1–DM, (b) mutant DQ2.5(Eβ86G, Qα31I, Hα24F)–CLIP1–DM), and (c) 
DR1–HA–DM (PDB ID: 4FQX). The residues α24F, α31I, α32F, α48F, α49G, 
α50R, α52A, α53S, α54F, α55E, β82N, β85V, β86G and β89F that form a 
hydrophobic pocket in DR and equivalent residues in DQ2.5 are shown in 
surface representation, colored white. The residue α51F is shown in blue slid 
surface with side chain in stick representation. The water molecule is shown in 
red sphere in panel a. The P1 pockets in different complexes are shown in the 










 distance between α51F and β82N during MD 
simulations. (left) The distance trajectory of the center of the phenyl group in 
α51F to the Cα of β82N in DQ2.5 in the wild-type (solid line) and mutant 
(dashdot line) DQ2.5–CLIP1–DM complexes. (right) The corresponding 
distances in the DQ2.5–CLIP1 crystal structure. 
2.4 Discussion  
In this study, the crystal structures of DQ2.5–CLIP1 and DQ2.5–CLIP2 
complexes have been determined at 2.73 Å and 2.20 Å resolutions, 
respectively. Although there are several available crystal structures of MHCII 
proteins with both canonical (the peptide orientation from N- to C-terminal in 
the peptide binding groove from P1 to P9) (PDB code 3PGD, 3PDO and 
4AH2) and flipped (the peptide orientation is inverted from C to N-terminal in  
the peptide binding groove from P1 to P9) orientations (PDB code 3PGC and 
4AEN)
52,66
 of CLIP1 peptide, this is the first time a crystal structure of a 
MHCII–CLIP2 complex has been reported. DQ2.5 is unusual in the fact that it 
associates with the canonical CLIP1 (Ii 83-101) as well as the non-canonical 
CLIP2 (Ii 92-107)
26
 peptides. Our study has revealed two unique structural 
features of DQ2.5 that may promote its association with CLIP2. Firstly, 
DQ2.5 has an unusually large P4 pocket that can accommodate the bulky P4 





groove that is electrostatically more compatible with the neutral CLIP2 
compared to the positively charged CLIP1 peptide.  
It was suggested that DQ2.5 cannot have the back bone hydrogen bond 
interaction with the P1 residues of the bound peptide
63
. In addition, the gluten 
derived (gliadin-α1a, LQPFPQPELPY, where the P1 residue is underlined) 
binds to DQ2.5 with two-fold higher affinity than its analog peptide 
containing norvaline (Nva) at P1 (~25µM)
67
. Nva is a non-proteinogenic alpha 
amino acid that is isosteric to Pro. This amino acid residue, however, has a 
primary amine group that has the ability to participate in the formation of 
hydrogen bond interactions. Therefore, gliadin-α1a must have an overall 
energetic advantage over the Nva substituted analog peptide for binding to 
DQ2.5, despite of the deficiency of a hydrogen bond at the P1 position. We 
propose that gliadin-α1a, and other peptides containing Pro at P1, have an 
entropic advantage that compensates for the lost enthalpy associated with the 
P1 hydrogen bond. 
Another unusual characteristic of DQ2.5 is its CLIP-rich phenotype, account 
for 53% of the eluted peptide pool
17
. It was proposed that the CLIP-rich 
phenotype of DQ2.5 is explained by DQ2.5–CLIP being poor substrates for 
DM
16,28
. During MHCII maturation, DM catalyzes the release of CLIP from 
the nascent MHCII
12
. Therefore, impaired DQ2.5–DM interaction will result 
in DQ2.5 molecules retaining their original CLIP cargo. In contrast, DR1 
expressing cells have a low abundance of CLIP
27
, which suggests that DR1 is 
a good substrate for DM. We found two structural elements in DQ2.5 that may 
lower its DM sensitivity. First, α51, which is a key DM contacting residue in 





Second, the peptide binding groove residues that form the α9–α22–α24–α31–
β86–β90 hydrogen bond network are not as free to move as the corresponding 
residues in DR1 (Figure 2.8). Therefore, DQ2.5 is less predisposed to the 
drastic secondary structure changes that DR1 undergoes upon DM binding. 
Our MD study showed that the α9–α22–α24–α31–β86–β90 hydrogen bond 
network is stable and the α51F of DQ2.5 cannot move into the P1 pocket upon 
DM binding. This is due to the blockage of the P1 pocket entrance by a water 
molecule which is part of the α9–α22–α24–α31–β86–β90 hydrogen bond 
network. To further test this idea, we disrupted the hydrogen bond network by 
mutating α24, α31 and β86 residues to the hydrogen bond non-permissible 
residues and then repeated the MD exercise. This time, α51F did translocate to 
fill the P1 pocket, similar to what happens in DR1 when interacts with DM. 
Our hypothesis that the α9–α22–α24–α31–β86–β90 hydrogen bond network 
leads to diminished DM sensitivity and ultimately to the CLIP-rich phenotype 
is supported by a recent study
28
. In that study the authors showed that the 
mutation of βE86A in DQ8 resulted in the increase of its DM sensitivity. In 
comparison with DQ2.5, DQ8 allele has the similar α9–α22–α24–α31–β86–
β90 hydrogen bond network, but lack of the α53 deletion mutation. Our 
hypothesis, however, is based on the assumption that the DR1–DM interaction 
mechanism is directly applicable to the DQ2.5–DM interaction. It remains to 
be seen if the DR1–DM interaction mechanism is truly universal. Even if this 
should prove not to be the case, the preferences of bulky hydrophobic anchor 




  indicate that these 
two molecules likely share the mechanistic feature of α51F translocating to fill 





Two other human MHCII alleles, which have a deletion mutation at α53 like 
DQ2.5 and also contain the same set of residues that make up the α9–α22–
α24–α31–β86–β90 hydrogen bond network in DQ2.5, are DQ4.4 
(DQA1*04:01-DQB1*04:02) and DQ7.5 (DQA1*05:05-DQB1*03:01)
72
. We 
predict that DQ4.4 and DQ7.5 could be poor substrates for DM and also have 
a CLIP-rich phenotype like DQ2.5. Interestingly, all three MHCIIs, namely 
DQ2.5, DQ4.4, and DQ7.5, are all associated with one or more human 
autoimmune disorders. DQ2.5 is associated with celiac disease and type 1 
diabetes, DQ4.4 is associated with juvenile idiopathic arthritis
73
, and DQ7.5 is 
associated with celiac disease
17,74
. Currently, there is no known mechanistic 
link between decreased DM sensitivity and human autoimmune disorders. 





Chapter 3  
The Molecular Mechanism behind the 
Peptide-editing Process of MHCII by DM 
Catalyst: an MD Study 
DM is important for editing the peptide from MHCII. The mechanism of this 
process could help to have a better view on how peptide was presented to T-
cell, as well as autoimmune disease. The process is studied by a pure 
computational technique, namely, MD simulations. 
3.1 Introduction 
MHCII protein forms a complex structure with an antigenic peptide that is 
later presented to T cell receptors. This antigen presentation triggers an 
immune response in the event of the pathogen entry (see chapter 2 for more 
details). The peptide repertoire of MHCII is accumulated with the help of DM, 
a non-classical MHCII protein. The 3D structure of DM is similar to that of 
MHCII, but lacks a peptide binding groove. Although MHCII proteins have 
great allelic variability, DM is non-polymorphic. This intracellular chaperone, 
DM, when in complex with other MHCII molecules, is responsible for (i) the 
removal of the CLIP peptide, (ii) the exchange of low to high binding affinity 
peptides
75
 and (iii) stabilization of peptide-free MHCII against MHCII 
inactivation
13,76,77
. In the absence of DM, the CLIP peptide is retained in 
MHCII and only a few antigens are presented to the T-cell receptors, making 
the process insufficient. The absence of DM also results in the aggregation of 







Currently, in the PDB there are only two crystal structures of the DR–
Antigen–DM complex60 at different pH conditions: at pH 6.5 (PDB ID: 
4GBX), and at pH 5.5 (PDB ID: 4FQX). The MHCII-bound antigen in this 
case is the hemagglutinin 306–318 peptide from influenza A virus (HA). The 
peptide exchange activity of DM is promoted under slightly acidic pH 
conditions (pH 5.5). The crystal structures show that when DM interacts with 
DR, the α43W residue of DR flips its χ1 side chain torsion angle by 120°. The 
α52-55 and β86-91 regions of DR also undergo secondary conformational 
changes (see chapter 2 for more details). The conformational change in α52-55 
results in an intramolecular change in DR with α51F occupying the aromatic 
and hydrophobic P1 pocket. As a consequence, the pocket is stabilized when 
the P1 residue of the peptide is released. In addition, the β89F residue that is 
close to the P1 pocket is also conjectured to contribute to that stabilization. 
Although the crystal structure clearly showed the interaction interface between 
DR and DM, the mechanism of conformational changes of residues in DR and 
DM from the non-interacting state (apo DR/DM) to the interacting state (holo 
DR/DM) remains unclear. The exact mechanism underlying DM catalysis and 
its pH dependence for the process of peptide exchange is also unknown. Even 
though both DR–HA–DM structures at pH 5.5 and pH 6.5 have the linked 
peptide starting at P2, the peptide is only visible in the electron density from 
P5 to P11 for the crystal structure at pH 5.5. The mechanism of peptide release 
from DR and the stabilization of empty DR by DM are poorly understood. 
This could result from the non-availability of the DR–DM complex structure 
in the absence of the peptide. It was previously shown that the peptide binding 







. It was proposed that when interacting with DM, DR could retain its 







Figure 3.1: The apo and the holo conformations of DR/DM proteins. (a) 
Crystal structure of DR–HA–DM complex at pH 5.5 (holo) (PDB ID: 4FQX), 
(b) superimposition of DR–CLIP1 (apo) (PDB ID: 3PDO) and DM (apo) 
(PDB ID: 2BC4) onto DR–HA–DM complex. The α1 (α2-79), α2 (α80-181), 
β1 (β-5-88), and β2 (β89-190) domains of DR are in marine, blue, pink and 
hot pink, respectively. The α1 (α13-93), α2 (α94-200), β1 (β3-88), and β2 
(β89-193) domains of DM are in green, forest, gray, and dark gray, 
respectively. The peptide of DR–HA–DM is in red. The peptide of DR–CLIP1 
is omitted for clarity. The backbone of the apo DR and the apo DM is 
represented in orange. (c) and (d) are the zoomed in views of the region in (b) 
that have been boxed in blue (β2 domains of DR and DM) and red (α1 and β1 
regions in DR, which are close to the P1 pocket), respectively. The two 
regions of (b) highlighted in boxes are the regions that have different 







To answer the question regarding the mechanism describing the changes in 
conformations of residues in DR and DM as the system undergoes from the 
non-interacting state to the interacting state, we carried out MD simulations of 
the DR–HA–DM complex where DR and DM have been taken from the 
crystal structures describing their apo conformations (Figure 3.1). The 
protonation states of ionizable residues correspond to the pH where the DR–
DM interaction occurs (pH 5.5). The apo and the holo terms for DM refer to 
the conformation of DM in its free state and in its DR-bound state, 
respectively. Similarly, the apo and the holo terms for DR refer to the 
conformations of the DR-peptide complex in its free state and DM-bound 
state, respectively. The effect of pH was studied by carrying out MD 
simulations of the same DR–HA–DM complex, but with the protonation state 
corresponding to pH 6.5. The peptide editing process by DM was studied by 
carrying out MD simulations of the DR–HA–DM crystal structure (PDB ID: 
4FQX) using the DR–HA (PDB ID: 3PDO) system as a control. Finally, the 
stabilization of peptide-free DR was examined by carrying out MD 
simulations of the peptide-free DR–DM complex, with the peptide-free DR 
system as a control. 
3.2 Introduction to MD simulations 
3.2.1 Definition and history 
Molecular dynamics simulation is a computational method that calculates the 
behavior of a molecular system as a function of time. This method provides 





biological molecules. Therefore, it is used to study the dynamic properties of 
biological molecules as well as their complexes. This method is also applied to 
determine and refine structures obtained by NMR and X-ray experiments. 
MD simulations were first introduced in 1955 by Fermi, Pasta, and Ulam
80
, in 
1957 by Alder and Wainwright
81,82
 and in 1964 by Rahman
83
. This was 
followed by simulations on a realistic system, i.e. liquid water
84
. The first 
simulations on a protein system
85
, the bovine pancreatic trypsin inhibitor, were 
carried out in 1977. Nowadays, MD simulations are performed on various 
systems, including protein-DNA complexes, protein-protein complexes, lipid 
systems, ligand-bound systems, studying protein folding etc.  
The basic algorithms of MD simulations include (i) dividing time into discrete 
time steps (ii) computing the forces on each atom at each time step depending 
on the molecular mechanic force field employed to model the interactions 
between atoms, (iii) determining the new position and velocity of each atom 
by numerically solving Newton's equations of motion (equation 3.1).  










 is the derivative of velocity   with respect to time  , 
   is mass of the atom  
     is the force on an atom i, and 
   is the position of the atom i 





equation can be numerically solved as 
             
     
 
 (3.2) 
and                 (3.3) 
where    is the time step 
3.2.3 Derivative of potential energy 
An energy function (also referred to as the molecular mechanic force field) 
was used to determine the force on each atom. The potential energy      is 
calculated as a sum of internal (or bonded) and a sum of external (or non-
bonded) terms 
                           (3.4) 
3.2.3.1 Bonded energy (       ) is calculated as 
                                                      (3.5) 
(1) The bond-stretching energy (               is the elastic interaction 
between a pair of atoms connected by a covalent bond and is calculated as 
follows 
               ∑   
         
     (3.6) 




  is the bond length at equilibrium the m
th
 bond 
   
  is the force constant that determines the strength of the bond 
(2) The angle bending energy (          ) is the interaction among three 
covalently-bonded atoms that form a stable angle. This energy term is 





            ∑   
         
     (3.7) 
where    is the m
th
 angle of the two adjacent bonds sharing a common atom 
   
  is the bond angle at equilibrium 
   
  is the force constant that determines the geometry of the bond 
(3) The torsional energy (                  ) is the interaction among four 
covalently-bonded atoms that form a stable dihedral angle. This energy term is 
calculated as follows 
                    ∑   
  [               ]  (3.8) 
where    is the m
th
 dihedral angle between two adjacent angles sharing a 
common bond 
    is the periodicity factor which determines the number of 
equilibrium dihedral angles in a 360  rotation 
    is the phase shift 
   
  is the amplitute 
3.2.3.2 Non-bonded energy (            is calculated as follows 
                      (3.9) 
(1) van der Waals interactions (      are induced electrical interactions 
between two or more closely located, but not bonded, atoms or molecules. 
     ∑ ∑     [(
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 ]       (3.10) 
where      is the distance between the atom   and the atom   
     is the van der Waals dissociation energy 
     is the collision diameter 
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 (3.11) 
where      are partial charges on the atom   and on the atom   
     is the distance between the atom   and the atom   
   is the dielectric constant 
The neighbour list (i.e. list of each atom and its immediate neighbours) is 
recomputed every few steps. 
The electrostatic potential is stronger and more long-range than the van der 
Waals potential. 
In MD simulations, the non-bonded interactions are more important than the 
bonded interactions, because these non-bonded interactions are the 
intermolecular interactions which affect the secondary structures and the 
assemblies. 
3.3 Methodology 
3.3.1 Preparation of Starting Structures for MD Simulations. 
500 ns MD simulations were performed on six systems. Each simulation 
carried out in triplicate with different initial conditions to ensure larger 





























DR–HA–DM P5 (7) 4FQX& -24 52331 







DR - 3PDO -13 39355 
*
The wild-type forms of α165D (DM), β46S (DM), and β92D (DM) were used 
because these residues were mutated in the crystal structures of DR–CLIP1 
complex and DM protein. 
&
 The wild-type forms of α65V (DR), and β30C (DR) were used because these 
residues were mutated in the crystal structures of DR–HA-DM. 
 
3.3.2 MD Simulations Protocol 
All-atom MD simulations were performed using the Gromacs-5.1.4
86
 package 
with the AMBER99SB force field
47
. SPC (simple point charge) water
87
 box 
with a minimum distance of 12 Å (Table 3.1) between any protein atom and 
the boundary of the box, was used to solvate each system. Periodic boundary 
conditions were applied. The protonation states of all ionizable residues were 
assigned according to the pKa predicted by the DEMM program
88,89
 (also see 
chapter 5 for more details). The structures were also manually inspected to 
correct for protonation states according to plausible/potential interactions, 




 in HIS. All 
systems were neutralized with sodium counter-ions (Table 3.1). All missing 
side chain atoms were built using MODELLER and hydrogen atoms were 





differing protonation states in the different MD systems or had pKa values 
different from the standard state values (Table 3.2). The residues that had the 
HIP form of Histidine (protonation at both N
ε1
 and N
δ2) were α5, α177 (DR), 
β16, β81, β111, β112 (DR), α16, α137, and α138 (DM). All the N-terminal 
and C-terminal residues were capped by an acetyl group (ACE) and an 
ethylamine group (NHE), respectively.  
The grid method was used to determine the neighbor list. This neighbour list 
and long-range forces were updated every 20 steps. The cut-off threshold for 
short-range forces, electrostatics and van der Waals was set to 10 Å. Particle 
Mesh Ewald method
90
 was applied for the treatment of long-range 
electrostatics interactions. The system pressure was maintained by coupling to 
a Parrinello-Rahman barostat at 1 bar with a coupling constant τP = 2 ps. The 




 along all box dimensions. 
The bond lengths were restrained using the LINCS algorithm
91
. The 
temperature of the system was coupled using velocity rescaling with a 
stochastic term. 
The system was first minimized with a maximum force of 900, 950 or 1000.0 
kJ/(mol.nm) in each of the triplicate runs respectively. The whole system was 
then submitted to MD simulations for 20 ns in the NVT ensemble, and 20 ns 
in the NPT ensemble, with the position restraints on heavy atoms of the 
proteins. This was followed by unrestrained NPT ensemble MD simulations 
which were performed for 500 ns, where T and P were set at 300 K and 1.0 
bar, respectively. The MD time step for integration was 2 fs, and the trajectory 





Table 3.2: Protonation states of the ionizable residues that differ from their 
canonical states 
Residue number Chain model 5.5 model 6.5 DR–HA–DM* 
21 A GLH GLU GLH 
29 A ASH ASP ASH 
30 A GLH GLU GLH 
33 A HIE HID HIE 
46 A GLH GLU GLU 
66 A ASH ASH ASH 
143 A HID HIE HIE 
149 A HIE HIE HIP 
167 A HIE HIE HIE 
2 B - - ASP 
176 B GLH GLU GLU 
177 B HIE HIE HIE 
20 C HIE HIE HIP 
35 C GLH GLH GLU 
180 C HIE HIE HIE 
6 D HID HID HIP 
31 D ASH ASP ASP 
47 D GLH GLU GLU 
61 D HIP HIE HIP 
82 D HID HID HIP 
141 D HIP HIE HIP 
145 D HIP HIE HIP 
161 D HIP HID HIP 
178 D HIE HIE HIE 
* 
the protonation state of ionizable residues in DR–DM , DR–HA and DR were 
the same as those in DR–HA–DM. 
 
where: HIE is HIS with a proton at N
ε1
; 
HID is HIS with a proton at N
δ2
;  





ASH is ASP with a proton at O
δ2
; 








3.3.3 Analysing the MD Simulations 
The temperature and potential energy of all the systems during the MD 
simulations were generated using the g_traj module of the GROMACS 
package. In all analyses, residues at the N- and C-termini were omitted from 
consideration as these regions undergo large fluctuations and may confound 
dynamics/correlation analysis. Only the following regions were considered: 
α6-178 (DR), β6-186 (DR), α18-194 (DM), and β6-190 (DM). The triplicate 
simulations were combined and different analyses of C
α
 RMSD, and RMSF of 
MD trajectories were performed with the help of the R program 
(http://www.R-project.org.) using the Bio3d package
92
. The PCA and distance 
analyses were done using in-house scripts. Movies were made using the 
VMD
93
 program. All the plots were obtained using the Python and GIMP 





 programs. The secondary structure assignment was calculated 




3.4.1 Model Structures 
 The modelled structure of the DR–HA–DM complex has a Cα RMSD of 1.55, 
1.13, 1.08, and 0.24 Å in comparison to crystal structures of the holo DR–HA–
DM at pH 5.5 (PDB ID: 4FQX), the holo DR–HA–DM at pH 6.5 (PDB ID: 
4GBX), the apo DR–CLIP (PDB ID: 3PDO), and the apo DM (PDB ID: 





3.4.2 Temperature and Potential Energy 
 
Figure 3.2: Potential energy (kJ/mol) during 500 ns MD simulations in the six 
systems. (a) Model_5.5, (b) model_6.5, (c) DR–HA–DM, (d) DR–DM, (e) 
DR–HA and (f) DR. Triplicate runs are shown in different colors (blue, green 
and red). 
The potential energies of all MD systems (Figure 3.2) are stable. The energy 
fluctuations are around -2,175, 000 kJ/mol for model_5.5 and model_6.5. 
Those energies are around -2, 295, 000 kJ/mol for DR–HA–DM or DR–DM 
systems. The systems without DM have energies around -1,655, 000 (DR–HA) 





than 0.1%. The temperature of all systems (Figure 3.3) during MD simulations 
is kept constant at 300K.  
 
Figure 3.3: Temperature (in K) during 500 ns MD simulations of the six 
systems. (a) Model_5.5, (b) model_6.5, (c) DR–HA–DM, (d) DR–DM, (e) 







3.4.3 Mobility of the Whole DR–DM Complex during 1.5 µs 
MD Simulations 
(a) DR mobility 
In general, the RMSD value with respect to the average structure (green line) 
is lower than the value with respect to the starting structure (blue line) (Figure 
3.4). The RMSD plot of the MD simulations for DR–HA was only shown up 
to 1µs because in one of the triplicate simulations the DR β2 domain rotates by 
about 90° compared to the crystal structure (Figure 3.6). We did look at the 
torsion angle but did not find that the rotation is due to a transition of a single 
torsion angle. It could instead be because of several angles. The rotation could 
be an artifact of the MD simulations, so we left that simulation out. Among the 
six systems, DR in peptide-free DR simulation has the most fluctuations (2.65 
Å and 1.93 Å with respect to the starting and average structures), while the DR 
protein in model_6.5 has the least fluctuation (average RMSD of 1.88 Å and 
1.52 Å with respect to the starting and average structures, respectively). 
(b) DM mobility 
For the DM fluctuation, among the four systems the DM protein in model_6.5 
has the most fluctuation (average RMSD of 2.21 Å and 1.38 Å with respect to 
the starting and average structures, respectively), while this protein in DR–DM 
systems has the least fluctuation (average RMSD of 1.82 Å and 1.07 Å with 
respect to the starting and average structures, respectively). 
This analysis gives the overall view of how each system stabilizes during 1.5 
µs MD simulations. Next we analyzed how each residue in each system has 






Figure 3.4: RMSD of DR protein. (a) Model_5.5, (b) model_6.5, (c) DR–HA–
DM, (d) DR–DM, (e) DR–HA and (f) DR. The RMSD values with respect to 
the starting and the average structures are in blue, and green, respectively. The 






Figure 3.5: RMSD of DM protein. (a) Model_5.5, (b) model_6.5, (c) DR–
HA–DM and (d) DR–DM. The RMSD values with respect to the starting and 
the average structures are in blue, and green, respectively. The x axis is the 
running time (in ns). The y axis is the RMSD values (in Å). 
 
Figure 3.6: The conformation of DR in the DR–CLIP1 crystal structure and in 
the 500 ns snapshot. The crystal structure is represented in tube with the color 






3.4.4 Average Atomic Mobility Reveals Important Region of 
DR/DM in MD Simulations 
(a) DR mobility 
The fluctuations of each residue in the six systems were analyzed using RMSF 
(root-mean-square fluctuation). The RMSF plot of DR in the six MD systems 
(Figure 3.7a) shows the different conformational behaviors in different parts of 
the protein. There are several regions where the fluctuations are higher than 2 
Å, namely, α35-40, α46-47, α49-65, α78, α99-100, α124-125, α156-159, 
α168-173, α177-178, β17-24, β43, β64-94, β104-116, β126-152 and β160-186. 
The missing region in the crystal structures, β104-116, has the fluctuation 
higher than 3 Å, with the peak at β108-109 in all the six systems. The β2 
domains in DR–HA–DM and DR-HA complexes have a fluctuation of more 
than 2 Å in almost all their component residues.  
Different pair-wise comparisons have been made. Only the regions that have 
RMSF differences higher than 1 Å are discussed here. Model_5.5 has residues 
where the RMSF values differ by more than 1 Å from model_6.5 at residues 
α37-38 (Figure 3.7b). This could be due to the fact that they are located in the 
loop region of the α1 domain. The RMSF values in model_5.5 are different 
from those in DR–HA–DM (Figure 3.7c) at the following regions: α168-173 
(α2 domain), β84-88 (peptide binding domains), and β133-145 (β2 domain). 
The RMSF value differences between DR–HA–DM and DR–DM (Figure 
3.7d) are at the α2 (α169-171) and the β2 (β133-145) domains. The DR 
proteins in the DR–HA–DM and DR–HA complexes (Figure 3.7e) show 
differences in the peptide binding region (α37-38, α53-58, β18-23, and β72-





peptide binding groove of the α chain (α53-58). This is close to the DM 
interaction site and P1 pocket. The RMSF values of DR–DM and DR are 
different only at the β72-82 region (Figure 3.7f). The DR–HA and DR systems 
have fluctuation differences at α17-24, α53-58, β67-71, β141-143 and β178-






















Figure 3.7: RMSF of DR in the six systems during 1.5 µs simulations. The 
RMSF values of model_5.5, model_6.5, DR–HA–DM, DR–DM, DR–HA and 
DR are represented in blue, green, red, cyan, black, and magenta, respectively. 
(a) All systems combination, (b) model_5.5 vs. model_6.5, (c) model_5.5 vs. 
DR–HA–DM, (d) DR–HA–DM vs. DR–DM, (e) DR–HA–DM vs. DR–HA, 
(f) DR–DM vs. DR, and (g) DR–HA vs. DR. The secondary structure assigned 
by DSSP are along the x-axis (above), where α-helix, β-strand and coil are in 
red, green and blue, respectively. The residue numbers of α and β chains 
(below) are shown in cyan and pink as in the Figure 3.1. 
(b) DM mobility 
The DM fluctuations of these four systems (Figure 3.8) are more consistent 
than the DR fluctuations. Fluctuations higher than 2 Å are observed at the 
following regions: α47-50, α63-72, α143-144, α147, α171, α182-183, β15-16, 
β38-40, β49, β108-110, β134-136, β152, and β166-170. The regions of α67-69 
and β140-146 have RMSF fluctuation higher than 3 Å in three out of the four 
systems (model_5.5, model_6.5 and DR–HA–DM). Among the four systems, 


















Figure 3.8: RMSF of DM in the four systems during 1.5 µs simulations. The 
RMSF values of model_5.5, model_6.5, DR–HA–DM, DR–DM, DR–HA and 
DR are represented in blue, green, red and cyan, respectively. (a) All systems 
combination, (b) model_5.5 vs. model_6.5, (c) model_5.5 vs. DR–HA–DM, 
and (d) DR–HA–DM vs. DR–DM. The secondary structure assigned by DSSP 
are along the x-axis (above), where α-helix, β-strand and coil are in red, green 
and blue, respectively. The residue numbers of α and β chains (below) are 
shown in green and gray as in the Figure 3.1. 
3.4.5 Principal Component Analysis Shows the Dynamical 
Correlation of the DR β2 Domain  
The essential dynamics of the six systems during the MD simulations were 
monitored by PCA (principal component analysis).  
(a) PCA of DR  
The porcupine plot of the first principal component shows the fluctuation of α-
helical region of peptide binding domain (α1 and β1), β2 domain and α2 
domain. The fluctuation of peptide binding region and β2 domain in DR 
increases in the absence of DM i.e. when comparing DR–HA–DM with DR–
HA and DR–DM with DR (Figure 3.9c, d, e and f). The β2 domain of DR in 
DR–HA–DM complex moves towards DM (Figure 3.9c), while in other five 
cases this domain moves away from DM (Figure 3.9d). Both model_5.5 and 
model_6.5 systems show less fluctuations, in comparison with DR–HA–DM. 
(b) PCA of DM  
Similar to RMSF, the fluctuation amplitude of PC1 in DM is smaller than in 
DR. The porcupine plots for DM show that only the β2 domains of DM in 
model_5.5 and DR–HA–DM have the tendency to come closer to the β2 
domains of DR (Figure 10). In model_5.5, model_6.5 and DR–HA–DM 






Figure 3.9: PC1 Porcupine plots of DR in the six systems. (a) Model_5.5, (b) 
model_6.5, (c) DR–HA–DM, (d) DR–DM, (e) DR–HA and (f) DR. The alpha 
chain is in blue and the beta chain is in pink. The red arrows depict the 






Figure 3.10: PC1 Porcupine plots of DM in the four systems. (a) Model_5.5, 
(b) model DR–HA–DM at pH 6.5, (c) DR–HA–DM, and (d) DR–DM. The 
alpha chain is in green and the beta chain is in gray. The red arrows depict the 







Figure 3.11: Dynamical cross validation matrix of DR in six systems. (a) 
Model_5.5, (b) model_6.5, (c) DR–HA–DM, (d) DR–DM, (e) DR–HA and (f) 
DR. The pink indicates negative correlation (anticorrelation), while the blue 
indicates positive correlation (correlation). The α and β chains along x and y 







Figure 3.12: Dynamical cross validation matrix of DM in four systems. (a) 
Model_5.5, (b) model_6.5, (c) DR–HA–DM and (d) DR–DM. The pink 
indicates negative correlation (anticorrelation), while the blue indicates 
positive correlation (correlation). The α and β chains along x and y axes are in 
green and gray as in the Figure 3.1. 
3.4.6 Dynamical cross-correlation 
The dynamical cross-correlation matrix (DCCM) of the C
α
 atoms indicates 
complex correlations in DR (Figure 3.11), but not in DM (Figure 3.12). DR 
has both positive and negative correlations, while DM is characterized by 
negative correlations.  
(a) DR correlation 
In DR–HA–DM and model_5.5 systems, the positive and negative correlations 
are more extensive than in the other four systems (DR–DM, model_6.5, DR–





with other regions, namely, α1, α2 and β1, but correlation (in blue) with itself. 
The β1 correlates with α2 but anticorrelates with α1. The α1/α2 correlation is 
not clear. 
(b) DM correlation 
The model_6.5 has more negatively correlated motion than the other three 
systems (model_5.5, DR–HA–DM and DR–DM). Positive correlation is less 
frequently observed than the negative correlation. 
3.4.7 Peptide Editing from DR by DM 
Peptide editing from DR by DM was also investigated in the DR–HA–DM and 
DR–HA complexes where HA starts from P5. The DR–peptide interaction was 
examined by the number of hydrogen bonds between HA peptide and DR 
protein (Figure 3.13 and Table 3.3). The side chain-side chain hydrogen bond 
interactions do not favor the HA-DR interaction (less than 22% for each 
hydrogen bond, see the first two rows of Table 3.3). Most of the hydrogen 
bond interactions are from the main chain atoms of the HA peptide and the 
side chain atoms of the DR protein. During 1.5 µs (3 x 500 ns) MD 
simulations, the average number of hydrogen bonds has increased to 6.5 (DR–
HA–DM) and 6.9 (DR–HA) in comparison to the crystal structure (five 
hydrogen bonds). Even though the peptide has not left the DR groove, in both 
the cases, the hydrogen bond number decreases for the last 50 ns of all 
triplicate simulations of the DR–HA system and one simulation of the DR–
HA–DM system. The decrease suggests the possibility of the HA peptide 






Figure 3.13: Number of hydrogen bond between DR and HA peptide during 
the MD simulations. (a) Location of residues that could make hydrogen bonds 
with HA, the hydrogen bond number in the (b) DR–HA–DM and (c) DR–HA 
complexes during triplicate 500 ns MD simulations. 
Table 3.3: Residence times (in %) of hydrogen bond interactions between DR 















 β71 Nε1 21.9 17.3 
P5 O
δ1
 β71 Nε2 13.7 7.5 
P5 O β71 Nε1 33.5 31.2 
P5 O β71 Nε2 48.1 41.5 
P5 N α62 Oδ1 42.7 18.6 
P7 O α69 Nδ2 90.6 89.4 





P9 N α69 Oδ1 81.4 89.3 
P10 O α76 Nε1 0.0 77.7 
P10 O α76 Nε2 86.0 19.3 
P10 N β57 Oδ1 93.9 39.7 
P10 N β57 Oδ2 0.0 27.1 
*
only hydrogen bond interactions that occur more than 10% in at least one of 
the two systems were shown in this table. The residence time is the number of 
MD simulation snapshots in which the hydrogen bond is formed over the total 
number of MD simulation snapshots (in percentage).   
3.4.8 Correlation of the Size of Peptide Binding Groove in 
Peptide-free DR in the Presence and Absence of DM 
Previous studies
79
 have shown that during 20 ns MD simulations the peptide-
free MHCII (in the absence of DM), some snapshots depict the closing of the 
peptide binding groove. Experimental studies
95
 showed that DM can stabilize 
the peptide-free DR. In this study, we used peptide-free DR as a control 
simulation in order to compare with the peptide-free DR–DM complex. The 





 distance of the periphery binding groove pairs; namely, αE55-βN82, 
αN62-βR71, and αN69-βW6179 (Figure 3.14). In the absence of DM, the Cα-
C
α
 distance between the two ends of the peptide binding groove either 
insignificantly increases (~3 Å) or decreases (~1 Å). The center of the groove, 




 distance of αN62-βR71 residues in one of the 
trajectories, decreases from ~16 Å to ~6 Å (Figure 3.14 and movie at 





the DR–DM simulation was also investigated. The smallest distance between 





is higher than in the case of the peptide-free DR simulations (6 Å). 
 
Figure 3.14: The conformational change of α-helices forming peptide binding 
groove. The change in (a) crystal DR–HA–DM (PDB ID: 4FQX), (b) DR–HA 









 distance of (d) 
αE55-βN82, (e) αN62-βR71, and (f) αN69-βW61 in DR–DM (left) and DR 
(right) MD simulations. The y axis is the distance in Å; the x axis is the time 
scale of MD simulations in ns. Different color lines are for triplicate 
trajectories. The corresponding distances in crystal structure of the DR–HA–
DM complex are shown in black dotted line. 
3.4.9 Conformational Changes of DM with Peptide-bound DR 
and Peptide-free DR 
To decipher the conformational changes in DM in the DR–DM and DR–HA–





α64Q to α77E (Figure 3.15) because this region shows high fluctuations in 
RMSF (Figure 3.8) and PCA (Figure 3.10) analysis. 
In all triplicate MD simulations, the secondary structure at the α69-75 region 
has a tendency of belonging to the coiled state in the DR–HA–DM complex 
more than in the DR–DM complex (Figure 3.16). The representative structures 
for DR–HA and DR–HA–DM complexes are in Figure 3.14b and c. The α69-
75 region changes from helical conformation in the crystal structure of DR–
HA–DM complex to coil conformation in MD simulations of DR–HA–DM. 
However, this conformational change from helix to coil is not observed in 
DR–DM simulations. The model_5.5 has a preference to form coil at residues 
from α69 to 71 only in the first run. In the region α72-75, the model_5.5 and 
model_6.5 prefer to adopt a coil conformation. Even though model_5.5, 
model_6.5 and DR–HA–DM complexes have the tendency of forming the coil 
conformation at α69-75 region, their localizations of the coil are different. 




 distances of α71-β75 residues 
(Figure 3.15, third column). In the DR–HA–DM complex, the tendency of 
forming coil results in widening of the DM groove by 4 Å in comparison with 
the crystal structure (movie at http://cospi.iiserpune.ac.in/cospi/data/)). 
Sometimes during 1.5 µs MD simulations that distance also increases in 
model_5.5, but decreases in model_6.5. The common feature between the 
complexes having α-helix to coil tendency at α69-75 region is that all these 








Figure 3.15: Conformation of the helical region in DM. (a) DR–HA–DM 
crystal structure (PDB ID: 4FQX), (b) model_5.5, (c) model_6.5, (d) DR–HA–
DM, and (e) DR–DM. All the snapshots are at 500 ns. The α chain of DM is in 
green and the β chain is in gray. The second column is the secondary 
conformation from α58 to α76. The order of stability of secondary structures 





 distance between αA71 and βG75. The crystal distance is 







Figure 3.16: (ψ, ϕ) diheral angles residues α69-75 in DM. (a) DR–HA, (b) DR–HA–DM, (c) model_5.5 and model_6.5. The ψ, ϕ 






In this study, 1.5 µs MD simulations (3 x 500 ns) have been performed on six 
systems in order to address the following issues: (i) to determine the 
conformational changes in DR/DM upon interaction, (ii) to identify the 
important residues for such conformational changes, (iii) to reveal the effect of 
pH on DR–DM interaction, (iv) to decipher the mechanism of peptide release 
from DR, and (v) to discover the mechanism of stabilization of peptide free 
DR by DM. The trajectories were analyzed for RMSD, RMSF, PCA, DCCM, 
distance and hydrogen bond interactions in order to answer these questions.  
3.5.1 Effect of pH on the DR-DM interaction 
The RMSF analysis shows that the fluctuation of DR/DM in model_5.5 and 
model_6.5 are very similar. On the other hand, the PCA analysis shows that 
the β1, β2 domains (in DR) and β2 domain (in DM) have differences in the 
directions of the fluctuations. The distance and DSSP display different 
motions in model_5.5 and model_6.5 at the DM α69-75 regions. However, the 
connection between these differences to the DR-DM interaction is not clear 
and remained to be answered. 
3.5.2 Mechanism of peptide editing from DR 
The editing mechanism of HA peptide from DR was examined in the DR-HA-
DM and DR-HA systems. None of the triplicate MD simulations showed the 
full removal of the peptide starting from P5 either in the presence or in the 





generate the conformational states that would induce the peptide to move out.  
3.5.3 Stabilization of peptide-free DR by DM 
The question on how DM stabilizes DR was investigated in the peptide-free 
DR system in the absence and presence of the DM protein. In our study, we 
detected the closing of the peptide binding groove in one of the triplicate 
simulations of peptide-free DR system in the absence of DM. This closing was 
not observed in the presence of DM. Although previous studies have also 
shown this conformational change
79
, this study shows that the closing is not a 
snapshot, but a stable conformation lasting more than 400 ns. 
3.5.4 Conformational change upon DR-DM complex formation 
and important residues for the interaction. 
The full conformational changes from the apo to the holo states of DR and 
DM were not observed during the sampling by the triplicate 500 ns 
simulations of model_5.5 and model_6.5. However, high fluctuation at the DR 
β2 domain and DM α1 domain for both models were seen during the 1.5 µs 
MD simulations. It could be possible that these domains are important for DR–
DM interactions. This work only focused on the backbone conformational 
change, the side chain conformational flexibility should be paid more attention 
in the future work. 
Currently, most DR–DM interaction studies have focused on the interactions 
involving the α1 and β1 domains95-97. Only a few random mutagenesis studies 
at this DR β2 domain, particularly at βD152N, βL184H, βS197N and βE187K 
showed reduction in the DM binding activity





residues were left out as they are near the C-terminal and obviously have high 
fluctuations. The residue β152 in the model_5.5, DR–HA–DM and DR–HA 
has fluctuations higher than 2 Å. In addition, experimental studies showed that 
some of the DR residues of the β2 domain, namely, βK98 and βR189, have 
different conformation in the peptide-bound and peptide-unbound 
conformations of DR
97. In this study, we showed that the β2 domain in DR has 
a high fluctuation (more than 3 Å) in the presence of DM at DR–HA–DM and 
model_5.5 complexes, but not in other structures. DM β2 domain in DR–HA–
DM and model_5.5 also tends to come closer to DR β2 domain. The PCA 
analysis also showed that the DR β2 domain fluctuated highly and correlated 
with the DM fluctuations. It could be possible that DR β2 domain could play 
important roles in the DR–DM interaction, for example, interacting with the 
β2 domain of DM to hold these two molecules together. The role of all 
residues of the β2 domain on MHCII function remains to be tested. 
The DM α69-76 region that is in the DR–DM interaction has a conformational 
change during the 500 ns MD simulations. DSSP analysis showed that these 
residues have a tendency to move from helix to loop conformation in DR–
HA–DM, model_5.5 and model_6.5 systems. All these three systems have the 
HA peptide bound. The conformational change in α69-75 residues in DM does 
not occur in the DR–DM complex. It could be possible that the conformational 
change in the α69-75 region affects the editing of HA peptide by some long-
range induced interaction. This effect could be tested by mutagenesis 
experiment on the residues of that region. The secondary structure of DM in 
this region was broken from α-helix to coil conformation, and hence, we 







. As the break in the secondary structure only occurs in the present of 







  Prediction of  
Polyproline Type II Helix Receptors 
The peptides that bind to MHCII have PPII conformation. As PPII is only the 
structural conformation, it could be possible that the PPII receptors should 
share their binding site specificity. This chapter tries to figure out these 
specificities and predicts whether a given protein could be the PPII receptors 
or not. 
4.1 Background and Motivation 
4.1.1 Definition and Properties of Polyproline II Helix (PPII)  
Protein secondary structure is a specific local structural conformation that is 
classified and stabilized by the intramolecular hydrogen bond pattern of the 
component residues
94
. For example, α helices and β sheets are considered 
regular secondary structures, while random coils, loops and turns are not. 
The PPII or polyproline II is another type of secondary structural 
conformation. Although proline residues are contained in many PPIIs, any 
residue can adopt this conformation, including residues with positive or 
negative charges, such as LYS, HIS, ARG, GLU, and ASP
99-104
. The (ϕ, ψ) 
backbone dihedral angles of PPII in the Ramachandran plot is roughly (-75º, 
+145º)
99,105
. PPII helices are left-handed and appear to have a three-fold 
rotational symmetry
106,107
 (Figure 4.1). In comparison with α helices PPII is 





The number of residues per turn for α helix is 3.6 while for PPII is only 3. 
 
Figure 4.1: Conformation of a PPII peptide. The peptide was taken from the 
complex with profilin (PDB ID: 2JKG) in (a) side view and (b) top view. 
4.1.2 Abundance of PPII 
The PPII was thought to be a rare conformation and there is a lack of the PPII 
assignment in most of the commonly used secondary structure assignment 
methods. However, this conformation was recently shown to occur more 





conformation with a length of three or more residues
108
. 
PPII helices were first found in fibrous proteins such as α-keratin and 
collagen
109,110
. Later, various globular proteins were shown to have this 
conformation
99,111
. PPIIs mediate inter-protein interactions
108,112
. This 
preference for PPII could be explained by the lack of intramolecular backbone 
hydrogen bond interaction in PPII helices. The backbone carbonyl and amide 
groups along the PPII helices are usually solvent exposed, so that PPII is free 
to make hydrogen bond with its receptor or solvent molecules. The advantage 
of such distinct chemical features is that it could mediate interactions even in 
the absence of high affinities. And hence, peptides with the PPII conformation 
have an ability to facilitate transient intermolecular interactions. Particularly, 
the PPII conformation is shown to frequently participate in protein-protein, 
protein-peptide or protein-nucleic acid interactions. These interactions are 
involved in signal transduction, transcription, antigen presenting, etc.
99
. There 
is a list of proteins (eight families) that are well-characterized to bind PPII, 
such as Src homology-3 (SH3) domain
113








myeloid, Nervy, and DEAF-1 domain (MYND)
117
, major histocompatibility 
complexes (MHC) class I
118
 and class II
52
. 
4.1.3 Significance of Predicting the Polyproline type II 
Helix Receptors 
The predictions of the PPII conformation have been extensively 
studied99,101,106,108. The interactions of PPII and individual PPII-binding protein 





bind to particular protein, such as SH3119 or MHCI or MHCII120 has been 
examined. Programs for predicting protein-peptide interactions, such as 
PepSite121, FlexPepDock122, GalaxyPepDock123, and CABS-dock124 could also 
be used to predict protein-PPII interactions. However, none of these programs 
use information from the known PPII-binding proteins to understand the 
common requirements for the PPII receptor proteins. It is likely that the PPII-
binding proteins, or the PPII receptors, could share their geometrical and 
biophysical features to interact with the peptides having the same 
conformation. And hence, our first aim is to characterize common features of 
the PPII-binding sites. These features were extracted from the known PPII-
binding proteins. The features were then used to identify the PPII-binding site 
in a query protein. To do that, we compared the query protein with templates 
from known PPII-binding proteins using the CLICK structural alignment 
program
125,126
. Only the structural hits that satisfied the binding criteria were 
chosen. Support vector machine (SVM) classification with different kernels
127
 
was applied to distinguish binding and non-binding hits. The hits which have 
the highest absolute SVM score were used as final identification of the binding 
site. The protein-PPII complexes were then built using a Monte Carlo 
refinement simulation. Finally, we also applied our protocol to a protein 
dataset of more than 17, 000 structures to find the new PPII-binding proteins. 
The detail information of experimental procedures, results and discussion are 






4.2.1 Dataset for Identifying Important Requirements to Bind 
PPII  
The homologous structures of all eight known PPII-binding proteins were 
searched using the PSI-BLAST
128,129
 program. The query sequences from SH3 
domain (PDB ID: 1CKA, chain A), WW domain (PDB ID: 1JMQ, chain A), 
GYF domain (PDB ID: 1L2Z, chain A), profilin (PDB ID: 2V8F, chain B), 
EVH1 domain (PDB ID: 4WSF, chain A), MYND domain (PDB ID: 2ODD, 
chain A), MHCI (PDB ID: 5C0D, chain A) and MHCII (PDB ID: 3PDO, 
chain B) were used. The queries were used to search over the entire PDB 
database. Five iterations were performed using an e-value cutoff of     . The 
sequence identity cutoff was set to 70%. Only those proteins that were bound 
to a PPII peptide were chosen. For NMR structures the models that had the 
highest number hydrogen bond interactions between PPII and protein were 
taken. There were 44 homologous structures with bound-peptides for the eight 
families discussed above (EVH1 (5), GYF (2), MHCI (3), MHCII (3), MYND 
(1), Profilin (2), SH3 (22) and WW (6)). 
4.2.2 Features to Characterize the PPII Binding Site 
Common requirements for the PPII-binding site were learned from the 44 
PPII-receptor structures. The following features were considered, namely: 
(1) Number of hydrogen bond was counted where the hydrogen bond was 
defined as in chapter 4.2.5.2. Different types of hydrogen bond interaction 





MC-MC, MC-SC, SC-MC and SC-SC, where the first atom name was from 
PPII and the second was from the receptor. 
(2) Depth was defined and calculated as in chapter 5.2. Both atomic and 
residue depth values were investigated. 
(3) Sequence entropy or conservation of each position was quantified based on 
multiple sequence alignment from the PSI-BLAST
128,129
. Two iterations were 
performed using a cutoff of      for e-value. The absolute entropy was 
calculated as the Jensen-Shannon divergence formula as follows: 
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We used the relative entropy, which was calculated as follows: 
   
         
             
 (4.2) 
where   is the entropy value of all positions  
4.2.3 Structural Alignments 
All the structural alignments were done using the CLICK structural alignment 
program125,126. This program makes pair-wise alignment between two PDB-





4.2.4 Constructing the RMSD-SVM Models. 
A vector of 11 features, most of which were RMSDs, was constructed. The 
features were: 







Trp) and NX, CX (from donor) in CLICK alignments, where NX is either N or 
O atoms from the side chain atoms of the residue, that donates its adjacent 
proton in a hydrogen bond interaction, and CX is the (i+2)
th
 atom where the 
NX atom is in the i
th
 position; 
 Feature 2. Number of matched atoms from the CLICK alignment; 
 Feature 3. Relative entropy as calculated in section 4.2.2; 
 Feature 4. RMSD of all atoms in Trp residues; 
 Feature 5. RMSD of C
α
 atom in Trp residues; 






 atoms in Trp residues; 
 Feature 7. RMSD of N
ε1
 atom in Trp residues; 
 Feature 8. RMSD of NX atom in Donor residues; 
 Feature 9. RMSD of features 7 and 8; 
 Feature 10. Summary of features 7 and 8; 
 Feature 11. RMSD of features 5, 7 and 8. 
All the possible combinations of these 11 features (2047 combinations for 
each kernel style (see below) and penalty parameter C) were trained/tested on 
the dataset of 44 structures. 
The RMSD of the closest oxygen atoms in CO groups to N
ε1





between template and target structures (or RMSDCO) was chosen as 
identification for a binding and a non-binding binary classification. If 
RMSDCO < 4 Å, the variable Y was set to 1 (binding), otherwise, it was set to -
1 (non-binding). 




Three different kernel types, including radial basis function (rbf), linear and 
polynomial kernels were used in the SVM. The penalty parameter C of the 
error term in SVM was set to 0.25, 0.5 and 0.75 in different trials. Nine 
different combinations of kernel types and penalty parameter were applied on 
the three different datasets (Table 4.1). The class weight for SVM was set as 
“balanced” to reduce the bias in the binding/non-binding frequency of the 
input data. 
As the dataset was small, a leave-one-family-out (LOFO) cross-validation was 
applied in the RMSD-SVM models. LOFO means that all the structures 
belonging to one families were completely left out and used as a testing set. 
Only the templates from nonhomologous structures were used. The RMSD-
SVM models were trained on the remaining data of other families and then 
tested on the testing set. For each structure, the alignment that had the highest 
SVM absolute score was chosen as a final prediction. The output from all the 
testing set then combined and reported. 
We also used nonhomologous and homologous dataset where all the 44 
structures were trained and tested against them. On the nonhomologous 
dataset, only nonhomologous templates were used for structural alignment, 





nonhomologous templates were used on the homologous set. 
4.2.5 Modeling the PPII Peptide into the Predicted Location of 
the Query Protein 
Monte Carlo simulations were used to build the PPII in the predicted location 
on the receptor (query) protein. The PPII from the template of the best 
alignment in section 4.2.4 was used in the model building. This PPII was 
transferred from the CLICK superimpose structure onto the query protein. In 
this study, we only built the main chain of the peptide but ignored the side 
chain atoms. The Monte Carlo simulations were carried out as follows: 
4.2.5.1 Monte Carlo Move Set 
From any given PPII-protein conformation, the following rigid body 
translation and rotation were performed on all PPII peptides coordinates  
a. Translation was performed along a random direction vector passing through 
the mean coordinates of the PPII with random amplitude ranging between -5 Å 
and +5 Å. 
b. Rotation was performed by a random angle ranging between -20° to 20°, 
around a randomly chosen direction vector passing through the mean 
coordinates of the PPII. 
4.2.5.2 Energy Calculations  
a. Number of Hydrogen Bonds Score (    ) was calculated as follows: 





where    is the total number of hydrogen bonds. 
Square of the number of hydrogen bonds was used to harmonically weight the 
score. A hydrogen bond is assumed to form when the acceptor-donor distance 
is less than 3.5 Å and the donor-acceptor-acceptor_antecedent angle is greater 
than 100°. NHBS score maximizes the total number of hydrogen bonds at any 
given point of the simulation. 
b. Restrained Hydrogen Bonds Score (    ) is the sum of distance score 
(    ) and angle score (    ) calculated as follows. 
     
                                    
             
       
where   is the distance between donor and acceptor. A factor of 6400 was 
multiplied to give more weight to distance score. 
     
                      
            
 (4.5) 
where   is the angle between donor, acceptor and acceptor antecedent. This 
angle has a maximum at 180° when three atoms, namely donor, acceptor and 
acceptor antecedent are in a line. 
               (4.6) 
     ensures the formation of hydrogen bond between TRP or Donor atoms 
of receptors and PPII peptide. 
c. Clash Score (CS): Any two atoms within 2.8 Å distance were considered 
clashing. Depending upon the atom type, these clashes were categorized as 
main chain-main chain clash (    ), main chain-side chain clash (    ) or 





                            (4.7) 
Square terms were used for      and      to harmonically increase the 
score compared to the      clashes that could be tolerated up to some extent. 
The scaling factors for each term were chosen approximately such that their 
scores satisfied the following inequalities: 
                              (4.8) 
d. Pseudo van der Waals Score (    ) was the total number of atom pairs 
whose distances were in the interval of 2.8 to 5.0 Å. This score was used to 
maximize the van der Waals energy term by increasing the density of protein 
atoms around PPII. 
e. Total energy ( ) of the system at any given point was calculated as follows:  
                           
4.2.5.3 Temperature and Gas Constant 
Temperature of the simulation was kept constant at 400K ( ) and Gas constant 
( ) as 2.10-3 kcal/(mol.degree)  
4.2.5.4 Selection/Rejection Criteria.  
Metropolis criteria were used with a   probability, 
                 (4.10) 
where       
 






4.2.5.5 Number of Independent Runs 
Total 40 independent runs (initialized by different random seeds) of Monte 
Carlo simulations were performed with 4000 Monte Carlo steps in each 
simulation. Each independent run leads to a unique model as none of the final 
models when compared to one another has an RMSD value equal to 0. 
4.2.5.6 Clustering the Models 
All 40 models were clustered into two sets using scipy hierarchical clustering 
“fcluster” module with “maxclust” criterion. The linkage matrix was created 
with “average” method. The model that had minimum RMSD with other 
models in the largest cluster was chosen as the representative model. 
All scripts were written in Python  
4.2.6 Dataset for Searching New PPII-binding Proteins 
The non-redundant dataset for homologous searching included structures 
determined by both X-ray and NMR methods. This dataset was taken from 
PISCES database
131,132
 with a pairwise sequence identity cutoff of 30%. Only 
protein structures with length between 40 and 500 amino acids were chosen. 






4.3.1 Features to Characterize the PPII-binding Site 
4.3.1.1 Hydrogen Bond Number 
We analyzed the numbers of hydrogen bond between PPII and its receptor for 
44 structures (Figure 4.2). The MC-MC hydrogen bond interactions are not 
present in the interactions between PPII and receptor. At the least, two MC-SC 
(in blue, the MC atom for this case is the carbonyl Oxygen) hydrogen bonds 
are observed in each structure of the eight known PPII-binding families. This 
trend in the MC-SC type is expected because each family in those eight PPII-
binding families could bind different sequence PPII peptides. One important 
observation is that in all 44 structures one of the receptor residues making the 
MC-SC hydrogen bond with PPII is always Trp. These Trp residues are also 
conserved in each family (see the entropy analysis in the subsection 4.3.1.4). 
And hence, in the prediction we required the PPII-binding site should have at 
least two residues that could make the side chain hydrogen bonds. One of 
these two residues should be Trp, and the donor side chain atoms of those 






Figure 4.2: The number of hydrogen bond interactions between PPII and the 
receptor for the 44 structures. The MC-SC, SC-MC and SC-SC hydrogen bond 
are in blue, red and green, respectively. The structure ID is the same as Table 
4.2. The family structure ID is following EVH1 – (1-5), GYF – (6-7), MHCI – 
(8-10), MHCII – (11-13), MYND – (14), Profilin – (15-16), SH3 – (17-38) 
and WW – (39-44). 
4.3.1.2 Depth Values of Hydrogen-bond-making Residues in the PPII-
binding Site 
We analyzed both the side chain atomic and residue depth for Trp and donor 
residues that make hydrogen bond interactions with PPII peptide. Trp residue 
depth (grey) values range from 3.72 to 5.15 Å, while the Trp N
ε1
 atomic depth 
(blue) has a smaller interval from 2.96 to 3.55 Å (Figure 4.3). The residue 
depth values (red) of donor residues range from 3.25 to 6.36 Å, while the 
atomic depth values (green) range from 2.89 to 4.37 Å. All the N
ε1
 atomic 
depth values of Trp residues in the PPII-binding sites are below 3.60 Å. The 





structures in the eight PPII-binding families with the exception of 4 cases in 
the MHCI and MHCII families. The depth values imply that both Trp and 
donor residues should be on the protein surfaces. This finding is consistent 
with the fact that in order to make hydrogen bond interactions with PPII, Trp 
should be exposed. And hence, we choose atomic depth threshold at 3.60 Å 
and 4.50 Å for N
ε1








Figure 4.3: The atomic and residue depth of Trp and Donor residues for 44 structures. The N
ε1
-Trp depth is in grey, residue 
Trp depth in blue, NX-Donor depth is in red and residue Donor is in green. The structure ID is the same as Table 4.2. The 
family structure ID is following EVH1 – (1-5), GYF – (6-7), MHCI – (8-10), MHCII – (11-13), MYND – (14), Profilin – 






Figure 4.4: The N
ε1
-NX distance in Å for 44 structures. The minimum and 
maximum distances are in blue and red, respectively. The structure ID is the 
same as Table 4.2. The family structure ID is following EVH1 – (1-5), GYF – 
(6-7), MHCI – (8-10), MHCII – (11-13), MYND – (14), Profilin – (15-16), 
SH3 – (17-38) and WW – (39-44). 
4.3.1.3 Distance between Trp and Other Donor Residues. 
The distances between N
ε1
 and NX atoms from the hydrogen-bond-making 
Trp residues and their neighbor donor residues, respectively were also 
investigated (Figure 4.4). It is clearly demonstrated that six out of eight 
families, except MHCI and MHCII have similar trend for the distance between 
N
ε1
 and NX atoms. However, all the eight families have the Trp-Donor pairs 
whose distances are below 12 Å. It means that it is possible to identify crucial 
residue pair in the interaction site using non-homologous structures. A cutoff 
threshold of N
ε1






4.3.1.4 Entropy Conservation 
The relative entropy (formula 4.2, page 72) of the hydrogen bond making Trp 
is calculated using Jensen-Shannon divergence (Figure 4.5). The minimal 
entropy value is 0.78, while the maximal entropy value is 1. This data show 
that the hydrogen bond-making Trp residues should be highly conserved. And 
hence, we used a cutoff of entropy of 0.7 for predicting the PPII-binding site. 
 
Figure 4.5: Entropy values of the PPII-binding Trp residues in 44 structures. 
The color is according to the family, particularly, EVH1 – red, GYF – green, 
MHCI – purple, MHCII – blue, MYND – grey, Profilin – pink, SH3 – cyan 
and WW – black. The structure ID is the same as in Table 4.2. 
4.3.2 Prediction Accuracy 
All the requirements for the PPII-binding site learning from previous sections 
were used for predicting the PPII-binding site. Even though the number of 





number of Trp-Donor pairs in the known PPII binding site, not all those pairs 
are actually PPII-binding sites. And hence, we used support vector machine to 
differentiate the actual binding sites. 
To identify the PPII-binding region, we first located all the Trp residues and 
its neighbor donor residues that satisfy the requirement for hydrogen bond 
interactions, depth value, conservation entropy, and the N
ε1
-NX distance. Then 
these structures were aligned with all templates of Trp-Donor residues using 







(Trp), NX (donor residues) and CX (donor residues). Only the alignments that 
have number of aligned atoms equal to 4 and CLICK RMSD value lower than 
0.6 or number of aligned atoms higher than 4 and CLICK RMSD value lower 
than 1 were chosen. The RMSD-SVM models for three different datasets 
(LOFO, Nonhomolog and Homolog), kernel, and penalty constant C as 
described in the method section, were constructed. The average RMSD values 
between the transferred PPII (taken from the PPII of the template structure in 
the CLICK alignment) and native PPII (taken from crystal structure of the 
target protein) were calculated (Table 4.1). In comparison of the three datasets 
(LOFO, Nonhomolog, and Homolog), the average RMSD values on LOFO 
dataset are highest, while those values on the Homolog dataset are lowest. The 
lowest RMSD values (3.80 Å) for the LOFO dataset is when C was equal to 
0.5 and the rbf kernel was used. The lowest RMSD values (3.51 Å) for the 
Nonhomolog dataset is when C was equal to 0.25 and the rbf kernel was used. 
The lowest average RMSD value (2.14 Å) was obtained on the Homolog 
dataset when C was set to 0.75 and the rbf kernel was used.  





values have a maximum at 4.92 Å and a minimum at 1.88 Å (Table 4.2). The 
RMSD has a mean of 3.01 Å and a standard deviation of 0.85 Å. The RMSD 
values before (2.14 Å) and after (3.01 Å) building the PPII using Monte Carlo 
simulations are not significant difference, but the usage of Monte Carlo 
simulations in modeling the peptide is to reduce the clashes between PPII 






Table 4.1: Statistics of RMSD between the transfer PPII and the native PPII in 
different SVM models. 






LOFO 2, 5 3.86 
Non-homolog 2, 5, 6, 8 3.51
*
 
Homolog 2, 4, 8 2.23 
0.5 
LOFO 3, 5, 9 3.80
*
 
Non-homolog 2, 5, 6, 8 3.56 
Homolog 2, 4, 5, 8 2.15 
0.75 
LOFO 1, 4, 5, 6, 7 4.06 
Non-homolog 1, 2, 5, 11 3.81 





LOFO 1, 3, 4, 10 4.12 
Non-homolog 1, 6, 9 4.21 
Homolog 2, 6, 7, 8, 10, 11 2.54 
0.5 
LOFO 1, 3, 4, 10 4.15 
Non-homolog 1, 4, 7, 10 4.22 
Homolog 2, 6, 7, 8, 10, 11 2.54 
0.75 
LOFO 1, 4, 9 4.1 
Non-homolog 1, 4, 8, 9 4.22 
Homolog 1, 2, 4, 5, 9, 11 2.48 
poly 
0.25 
LOFO 6, 11 3.9 
Non-homolog 1, 2, 3, 4, 6, 7, 8 3.81 
Homolog 1, 2, 6, 8, 9, 11 2.25 
0.5 
LOFO 6 4.02 
Non-homolog 1, 2, 3, 4, 6, 7, 10 3.8 
Homolog 2, 3, 5, 6, 8, 10, 11 2.19 
0.75 
LOFO 6 4.02 
Non-homolog 1, 2, 3, 4, 6, 8, 10 3.83 
Homolog 2, 3, 5, 6, 8, 10, 11 2.19 
*
is for the best RMSD values 
4.3.3 Benchmarking with Other Protein-Peptide Interaction 
Prediction Methods 
We also compared our prediction with state-of-the-art methods in predicting 









search the binding site of the fully flexible given peptide in the receptor with 
small fluctuations of its backbone. In GalaxyPepDock a template from 
database which is homologous to the given receptor is determined and then 
models are built using energy-based optimization. In comparison, our method 
on homologous template prediction has the RMSD of 2.14 Å and 3.01 Å for 
transfer peptides and peptides built by Monte Carlo simulations, respectively. 
The average RMSD of all built models by our method (3.01 Å) are lower than 









Family PDB ID transfer Monte 
Carlo 
CABS Galaxy 
1 EVH1 1K5D 1.7 1.88 20.64 4.82 
2 EVH1 1RRP
*$
 4.78 3.49 23.48 3.96 
3 EVH1 4B6H 2.82 3.34 10.76 4.1 
4 EVH1 4WSF
$
 4.53 4.08 3.76 2.74 
5 EVH1 5J3T 0.43 2.04 11.4 2.78 
6 GYF 1L2Z 3.07 2.05 6.67 3.12 
7 GYF 3FMA 3.07 4.92 18.43 22.84 
8 MHCI 2QRT
*
 2.65 2.5 8.99 1.36 
9 MHCI 4CW1
*$
 4.8 4.7 12.19 2.64 
10 MHCI 5C0D 1.3 3.11 9.38 21.29 
11 MHCII 1JK8 1.08 1.99 - 2.32 
12 MHCII 3PDO
*
 3.4 2.34 - 1.8 
13 MHCII 4P57 1.44 2.31 - 1.38 
14 MYND 2ODD
*
 2.41 2.83 10.36 2.5 
15 Profilin 2PBD 0.72 2.27 10.98 1.85 
16 Profilin 2V8F 0.72 2.39 15.5 1.82 
17 SH3 1CKA 1.92 2.64 7.29 1.09 
18 SH3 1GBQ 0.84 1.92 6.11 1.28 
19 SH3 1SEM 1.62 1.98 9.6 1.86 
20 SH3 1UTI 1.51 2.48 8.28 2.87 
21 SH3 1YWO 1.55 2.57 9.33 2.1 
22 SH3 2DF6 2.08 4.3 5.61 3.08 
23 SH3 2DRM 1.61 2.15 4.14 1.07 





25 SH3 2LCS 2.79 3.18 6.39 2.67 
26 SH3 2ROL 3.54 3.73 9.53 3.09 
27 SH3 2RPN 1.4 4.27 3.78 3.19 
28 SH3 2VKN 0.98 2.29 6.53 2.48 
29 SH3 2VWF 2.21 2.49 11.27 2.57 
30 SH3 3I5R 0.82 3.28 13.67 1.14 
31 SH3 3U23 1.74 4.8 4.08 1.82 
32 SH3 3ULR 1.73 2.63 7.7 11.79 
33 SH3 4CC2 3.76 2.34 9.17 1.54 
34 SH3 4F14 0.86 2.86 7.24 2.56 
35 SH3 4HVW 2.35 3.37 11.39 1.74 
36 SH3 4J9C 1.61 2.78 7.58 1.5 
37 SH3 4LNP 2.27 2.43 9.36 1.37 
38 SH3 4U5W 2.27 4.48 12.17 4.06 
39 WW 1JMQ
*
 2.43 3.55 12.64 3.98 
40 WW 2EZ5
*
 2.41 2.62 11.68 2.74 
41 WW 2JO9 0.88 3 6.75 2.87 
42 WW 2LAJ
*
 2.93 3.88 8.3 4.12 
43 WW 2LAW
*
 3.13 4.02 7.63 4.28 
44 WW 2LAZ
*
 2.62 3.56 7.06 6.36 
RMSD - - 2.14 3.01 9.60 3.70 
Standard 
deviation 
- - 1.09 0.85 4.19 4.38 
*
 Cases where template and target structure are nonhomologous 
$
 Cases where the predictions of transfer RMSD higher than 4 Å 
 “transfer” refers to the PPII peptide from template structure was 
transferred into the target structure. 






“Average” refers to the average values of RMSD among 10 models built 
by protein-peptide prediction methods (either by CABS-dock or 





4.3.4 Searching possible PPII receptors in the PDB 
We have used our protocol to predict possible PPII receptors among 17, 000 
non-redundant (30% sequence identity) proteins from the PDB. 138 structures 
were predicted as having the PPII-binding sites (Table 4.3). 13 cases (of the 
138) belong to the eight known PPII receptor families. The other 125 
structures are from different families, some of which have the function in 
signaling network and immune response. Three interesting examples are 
NADPH oxidase (PDB ID: 1OEY) (ubiquitin-like), clathrin adaptor (PDB ID: 
1KYF) and secretion chaperon-like (PDB ID: 1JYA). In these cases, the 
location of Trp and Donor residues that we predicted to bind PPII actually has 
a bound-peptide (Figure 4.6b) or a part of the partner protein (Figure 4.6a,c). 
The RMSD values between the transferred peptides from the templates and the 
native peptides range from 3.36 to 3.69 Å. In addition to these three cases, the 
other 18 cases, in which the predicted location of Trp-Donor residues are in 
the homo-oligomer interaction sites (Table 4.3). The homo-oligomers do not 










Table 4.3: List of the predicted PPII-receptors (
*
cases where the predicted PPII-binding sites are in the interaction sites with its 
homo-oligomers) 





12AS A 84 76 Class II aaRS and biotin synthetases Aspartate-ammonia ligase 
1A0T P 361 337 Transmembrane beta-barrels LamB porin 
1A8D A 10 7 
beta-Trefoil, Concanavalin A-like 
lectins/glucanases 
Clostridium neurotoxin, receptor binding 
(C-terminal) 
1ACF A 5 2 Profilin-like Profilin 
1B3T A 497 503 Ferredoxin-like 
Epstein Barr virus nuclear antigen-1, DNA-
binding domain 
1B5Q A 413 285 FAD/NAD(P)-binding domain Flavin containing amine oxidoreductase 
1B8K A 18 20 Cystine-knot cytokines Nerve growth factor family 
1B9M
*
 A 183 186 
OB-fold, OB-fold, DNA/RNA-binding 3-
helical bundle 
Bacterial regulatory helix-turn-helix protein, 
lysR family, TOBE domain 
1BGF A 67 37 Transcription factor STAT-4 N-domain STAT protein, protein interaction domain 
1BIA A 42 46 
Class II aaRS and biotin synthetases, SH3-
like barrel 
HTH domain, Biotin/lipoate A/B protein 
ligase family 
1BM8 A 81 33 Mlu1-box binding protein MBP1 KilA-N domain 
1BQU
*
 A 138 192 Immunoglobulin-like beta-sandwich 
Interleukin-6 receptor alpha chain, binding, 
Fibronectin type III domain 
1BS0 A 6 3 
PLP-dependent transferase-like (DNA-
binding domain) 
Aminotransferase class I and II 
1BVY F 536 574 Flavodoxin-like Flavodoxin 










 1 174 64 4-helical cytokines Ciliary neurotrophic factor 
1COZ A 9 74 Adenine nucleotide alpha hydrolase-like Cytidylyltransferase 
1CV8 A 165 143 Cysteine proteinases Staphopain peptidase C47 
1CXQ A 97 76 Ribonuclease H-like motif Integrase core domain 
1D02 A 194 12 Restriction endonuclease-like Type II restriction enzyme MunI 
1D0D A 25 37 BPTI-like 
Kunitz/Bovine pancreatic trypsin inhibitor 
domain 
1D2S A 47 100 Concanavalin A-like lectins/glucanases Laminin G domain 
1DDW A 76 24 PH domain-like barrel WH1 domain 
1DI2 A 153 126 dsRBD-like Double-stranded RNA binding motif 
1DMG A 100 97 Ribosomal protein L4 Ribosomal protein L4/L1 family 
1DS1 A 285 288 Double-stranded beta-helix 




 A 306 310 
P-loop containing nucleoside triphosphate 
hydrolases 
Thymidine kinase from herpesvirus 
1E6U A 276 202 NAD(P)-binding Rossmann-fold domains 
NAD dependent epimerase/dehydratase 
family 




1EG3 A 81 83 
WW domain-like, EF Hand-like, EF Hand-
like 
WW domain, EF hand, EF-hand 
1EQ2
*
 A 81 84 NAD(P)-binding Rossmann-fold domains 
NAD dependent epimerase/dehydratase 
family 
1F0K A 136 137 
UDP-Glycosyltransferase/glycogen 
phosphorylase 









1FSU A 479 438 Alkaline phosphatase-like Sulfatase 
1GCQ
*
 C 654 636 SH3-like barrel Variant SH3 domain 
1GSA A 265 130 ATP-grasp, PreATP-grasp domain 
Prokaryotic glutathione synthetase, ATP-
grasp domain (N-terminal) 
1H4X A 93 98 SpoIIaa-like STAS domain 
1H8A C 179 166 DNA/RNA-binding 3-helical bundle Myb-like DNA-binding domain 
1HDK A 75 72 Concanavalin A-like lectins/glucanases Galactoside-binding lectin 
1HQI A 64 61 
Monooxygenase (hydroxylase) regulatory 
protein 
MmoB/DmpM family 
1HT6 A 212 299 
Glycosyl hydrolase domain, TIM beta/alpha-
barrel 
Alpha-amylase C-terminal beta-sheet 
domain 
1HYO A 371 367 SH3-like barrel, FAH 
Fumarylacetoacetate (FAA) hydrolase 
family (N-terminal) 
1HZ4 A 208 211 alpha-alpha superhelix Transcription factor MalT domain III 
1I71 A 35 70 Kringle-like Kringle domain 






Protein kinase-like (PK-like) Alpha-kinase family 
1IAR B 193 190 Immunoglobulin-like beta-sandwich 




 A 287 270 Thiamin pyrophosphokinase 
Thiamin pyrophosphokinase, vitamin B1 
binding domain 
1IOJ A 48 41 Fragments of the apolipoproteins The apolipoprotein C-I (The apoC-1) 
1J2R
*
 A 143 115 Isochorismatase-like hydrolases Isochorismatase family 
1J58 A 183 171 Double-stranded beta-helix Cupin, Cupin 








1JL1 A 72 120 Ribonuclease H-like motif RNase H 
1JOV A 242 229 Supersandwich Aldose 1-epimerase 
1JY1 A 506 392 Phospholipase D/nuclease Tyrosyl-DNA phosphodiesterase 
1JYA A 41 90 Secretion chaperone-like Tir chaperone protein (CesT) family 
1JYH A 134 144 Probable bacterial effector-binding domain GyrI-like small molecule binding domain 
1JYK A 196 136 Nucleotide-diphospho-sugar transferases Nucleotidyl transferase 
1K0H A 77 89 Phage tail proteins Phage Head-Tail Attachment 
1K5N A 146 147 Immunoglobulin-like beta-sandwich, MHC 
Class I Histocompatibility antigen, domains 
alpha 1 and 2 
1K77 A 226 257 TIM beta/alpha-barrel Xylose isomerase-like TIM barrel 
1KAE A 248 353 ALDH-like Histidinol dehydrogenase 
1KFT A 54 74 SAM domain-like Helix-hairpin-helix motif 
1KJQ A 139 178 
Barrel-sandwich hybrid, PreATP-grasp 
domain 
ATP-grasp domain 
1KKO A 224 217 
TIM beta/alpha-barrel, Enolase N-terminal 
domain-like 
Methylaspartate ammonia-lyase N-terminus 
1KNZ A 134 87 NSP3 homodimer Rotavirus non-structural protein NSP3 
1KOL A 156 353 
GroES-like, NAD(P)-binding Rossmann-fold 
domains 
Alcohol dehydrogenase GroES-like domain, 
Alanine dehydrogenase/PNT 
1KT6 A 54 91 Lipocalins 
Lipocalin / cytosolic fatty-acid binding 
protein family 
1KYF A 841 840 Immunoglobulin-like beta-sandwich 
Adaptin C-terminal domain, Alpha adaptin 
AP2, C-terminal domain 
1LBA A 46 41 N-acetylmuramoyl-L-alanine amidase-like N-acetylmuramoyl-L-alanine amidase 
1LG4 A 82 83 Prion-like Prion/Doppel alpha-helical domain 














DNA/RNA-binding 3-helical bundle Homeo-prospero domain 
1MIW A 400 392 Poly A polymerase, Nucleotidyltransferase 
 tRNA nucleotidyltransferase domain 2 
putative 
1MUN A 142 154 DNA-glycosylase 
Iron-sulfur binding domain of endonuclease 
III 
1N4Q B 235 188 alpha/alpha toroid 
Prenyltransferase and squalene oxidase 
repeat 






GTPase activation domain, GAP 
GTPase-activator protein for Ras-like 
GTPase 
1NG2 A 173 193 SH3-like barrel SH3 domain 
1NO1 A 63 33 
Replisome organizer (g39p helicase 
loader/inhibitor) 
Loader and inhibitor of phage G40P 
1O59 A 326 247 Galactose-binding domain-like Allantoicase repeat, Allantoicase repeat 
1O6W A 15 26 WW domain-like WW domain 
1O9I
*
 A 132 33 Ferritin-like Manganese containing catalase 
1OEY A 395 425 beta-Grasp (ubiquitin-like) PB1 domain 
1OPC A 224 226 DNA/RNA-binding 3-helical bundle 
Transcriptional regulatory protein, C 
terminal 
1ORR A 241 335 NAD(P)-binding Rossmann-fold domains 
NAD dependent epimerase/dehydratase 
family 
1OUW A 87 12 beta-Prism I Jacalin-like lectin domain 
1OV2 A 50 29 RAP domain-like 










1OWW A 40 46 Immunoglobulin-like beta-sandwich Fibronectin type III domain 
1OZJ A 125 94 SMAD MH1 domain MH1 domain 
1PKH A 115 133 beta-clip dUTPase 
1PM4 A 95 72 Superantigen (mitogen) Ypm Yersinia pseudotuberculosis mitogen 
1PMI A 109 18 Double-stranded beta-helix Phosphomannose isomerase type I 
1PUJ A 162 160 
P-loop containing nucleoside triphosphate 
hydrolases 
50S ribosome-binding GTPase 
1Q9C A 143 85 Histone-fold Core histone H2A/H2B/H3/H4 
1QO0 D 19 43 Flavodoxin-like ANTAR domain 
1QQE A 192 196 alpha-alpha superhelix Soluble NSF attachment protein, SNAP 
1QRV A 10 43 HMG-box HMG (high mobility group) box 
1QWD A 77 86 Lipocalins Lipocalin-like domain 
1R6X A 353 374 
Adenine nucleotide alpha hydrolase-like 
(PUA-like) 
PUA-like domain, ATP-sulfurylase 




1RGX A 39 82 Resistin Resistin 
1RHS A 6 14 Rhodanese/Cell cycle control phosphatase Rhodanese-like domain 
1RP0
*
 A 176 160 FAD/NAD(P)-binding domain Thi4 family 
1RXD A 78 67 (Phosphotyrosine protein) phosphatases II Protein-tyrosine phosphatase 
1RXQ
*
 A 46 177 DinB/YfiT-like putative metalloenzymes DinB superfamily 
1RY3 A 25 18 Leucocin-like bacteriocin Class II bacteriocin 
1RY9
*
 A 34 55 Secretion chaperone-like Invasion protein B family 
1S1D A 186 128 5-bladed beta-propeller Apyrase 
1S5D A 84 127 ADP-ribosylation Heat-labile enterotoxin alpha chain 









1SG4 A 200 201 ClpP/crotonase Enoyl-CoA hydratase/isomerase family 
1SPK A 62 44 SH3-like barrel Variant SH3 domain 
1SQ4 A 229 231 Double-stranded beta-helix Cupin domain, Cupin domain 
1SQG A 152 148 NusB-like, methyltransferases NusB family, NOL1/NOP2/sun family 
1SYX B 30 52 GYF/BRK domain-like GYF domain 
1T0B
*
 A 146 131 Flavodoxin-like Trehalose utilisation 
1T1G A 305 230 Subtilisin-like Subtilase family 
1T33 A 73 65 
DNA/RNA-binding, Tetracyclin repressor-
like 
Bacterial regulatory proteins, tetR family, 
Domain of unknown function 
1TG0 A 60 40 SH3 domain SH3 domain 
1TJO
*
 A 45 53 Ferritin-like Ferritin-like domain 
1TLY A 216 262 Transmembrane beta-barrels 
Nucleoside-specific channel-forming 
protein, Tsx 
1TWD A 9 202 TIM beta/alpha-barrel CutC family 
1U0T
*
 A 290 304 NAD kinase/diacylglycerol kinase-like ATP-NAD kinase 
1U3E M 18 3 
DNA-binding domain ( intron-encoded 
endonucleases) 
NUMOD4 motif, HNH endonuclease 
1U7K
*
 A 18 23 
Retrovirus capsid protein, N-terminal core 
domain 
Gag P30 core shell protein 
1UDD A 28 212 Heme oxygenase-like TENA/THI-4/PQQC family 
1UII A 98 99 Parallel coiled-coil Geminin 
1UTE A 171 168 Metallo-dependent phosphatases Calcineurin-like phosphoesterase 
1UUJ
*
 A 18 55 
Lissencephaly-1 protein (Lis-1, PAF-AH 
alpha)  
LisH 
1UV7 A 114 116 RRF/tRNA synthetase additional domain-like Type II secretion system (T2SS), protein M 










1V2X A 71 73 alpha/beta knot SpoU rRNA Methylase family 





 A 25 29 RRF/tRNA synthetase additional domain-like 
Threonyl and Alanyl tRNA synthetase 
second additional domain 
1V64 A 26 52 HMG-box HMG-box domain 
1V88 A 17 23 PH domain-like barrel PH domain 










Figure 4.6: New cases of the PPII-binding proteins. (a) NADPH oxidase (PDB ID: 1OEY), (b) Clathrin adaptor (PDB ID: 1KYF) 
and (c) Secretion chaperon-like (PDB ID: 1JYA). The peptides or the parts of the partner proteins are shown in pink and the receptors 
are shown in light brown. The donor, Trp residues, and peptides are in stick representation. The hydrogen bond interactions between 






The aim of this study is to (i) reveal the key features of the PPII receptor sites, 
(ii) accurately model the PPII-protein interactions and (iii) identify new PPII-
binding proteins from the PDB. The results show that the specificities in the 
number of hydrogen bond, depth values, entropy conservation and N
ε1
-NX 
distance could be used as the signals for PPII receptor sites. The Trp residues 
that are highly conserved in each PPII-binding site are shown to be important 
in the PPII recognition. The importance of Trp residues could be explained by 
their possibility of making hydrogen bond from their side chain atoms, their 
potentials on making hydrophobic and van der Waals interactions. Recently, it 
is shown that in the SH3 domain of CASKIN2 scaffolding protein, an Arg 
residue has replaced the PPII recognizing Trp, and hence, CASKIN2 lacks the 
ability to interact with the calmodulin kinase domain. The mutagenesis from 
Arg to Trp restores the interaction
135
. Another example showing the 
importance of Trp is in the case of smurf2 WW3 domain. When Phe is 
presented at the hydrogen bond making Trp position,  the binding affinity to 
the PPII peptide decreases in comparison with the canonical WW3 domain
136
. 
The average RMSD of the PPII modeled by Monte Carlo simulations and the 
native PPII has a mean of 3.01 Å and a standard deviation at 0.85 Å. In 
comparison with other available protein-peptide interaction prediction 
methods, particularly CABS-dock and GalaxyPepDock, our method predicts 
the PPII with lower RMSD values. The CABS-dock method, in addition, only 
works in the single chain proteins, and hence, for the heterogous structures 





other hand, allows users to submit only three jobs at a time. The 
GalaxyPepDock also uses the homologous to find the location of peptide. The 
other protein-peptide prediction programs, such as PepSite or FlexPepDock 
are not user friendly and are out of the benchmarking. Using only two residues 
as the templates, the RMSD of the modeled and the native PPII peptides in our 
method is better than both GalaxyPepDock and CABS-dock methods. 
When applying our method on a data set of 17005 structures with the sequence 
identity lower than 30%, we detected 125 new PPII-binding proteins, which 
have not been trained in our model. Three of these structures have the 
peptides, or stretches of protein that are bound exactly to the Trp and donor 
residues we predicted. A web-server for this prediction will be available soon. 
The user gets not only the key residues for binding PPII, but also the location 
of the PPII backbone atoms. 
Our assumption in this study is that the conformation of the PPII receptor sites 
in the PPII bound and unbound conditions would not dramatically change and 
hence, it cannot account for the conformational flexibility. Another limitation 
is that our method requires at least two hydrogen bond interactions between 
the PPII and its receptors, and hence, some of the receptors, which make only 
one hydrogen bond interactions or lost the Trp residue, could not be predicted. 
For example, the collagen-bound protein
137-139
 does not have hydrogen bond 
making Trp residue, and could not be predicted by our method. This limitation 
could be avoided if this protocol is generalized to two hydrogen bond 
requirement, without preferences on Trp residues. In addition, while we 
consider only the hydrogen bond interactions between the receptors and the 





of the difficulty of this feature. This PPII prediction protocol is only concerned 
about the conformation of proteins, as well as, peptides, but not their 
sequence. The optimal sequences of the protein and peptide could be dealt 
with in future as an extension of this study. However, this first PPII receptor 
prediction model could be beneficial for detecting the PPII receptor in 
signaling network and immune system. The protocol in this study could be 
generalized for other conformations, such as alpha helical conformation. As 
the PPII peptide could be a potential source of new peptide-based novel 
drugs
140,141
, a search for the receptor of the PPII could benefit the 
understanding of pathways, as well as, the side effect of synthetic peptides. As 
this study only predicts whether or not the protein could bind the PPII, the 
specificity of the peptide sequence has not been considered. The further 
extension of this work could be on predicting the affinity of a particular PPII 





Chapter 5  
pKa Prediction of  
Ionizable Amino Acid Residues in Proteins 
The interaction or a function of a protein highly correlates with the charge of 
its ionizable residues. The charges are monitored by the protonation state of 
these residues. One measurement can be used to identify the protonation state 
is pKa, and in this chapter, we explained how we can predict the pKa of 
ionizable residues in protein 
5.1 Background and Motivations 
5.1.1 Significance of the pKa Prediction 
The acid dissociation constant, or more commonly its negative logarithm (base 
10), pKa, measures the protonation strength of an acid in solution. In proteins, 
this pKa term is also used to quantify the protonation state of ionizable amino 
acid residues including ASP, GLU, HIS, LYS, and ARG. The importance of 
pKa in the protein structure and the protein function is illustrated by the fact 
that about 25% of protein residues and 65% of residues in the active sites
142
 
are ionizable. The change of pH can induce the shift of the ionizations, which 
affects electrostatic interactions, as well as, the molecular structure and the 
function. Particularly, the protonation states of residues modulate many 











 and other functions
149-152





pKa is a powerful means of investigating the protein function. To decipher 
these pH-dependent processes, it is important to correctly estimate the pKa 
values; which could reveal the underlying physical principles guiding these 
processes. 
pKas of ionizable amino acid residues depend on their immediate 
protein/solvent environment. In bulk solvent, the environmental 
physicochemical properties of a chemical group are simply the properties of a 
homogeneous aqueous solution of water. However, proteins have 
inhomogeneous environment and their physicochemical properties could 
drastically change across different regions in proteins. For example, the 
average dielectric constant of a polar chemical group in bulk solvent could be 
about ~80, while its value in protein is around ~20 - 30 on the protein surface 
and ~6 - 7 in the protein interior
153
. Therefore, it is not surprising that the same 
chemical group or amino acid residue would behave differently depending on 
their location in proteins. 
A popular experimental method to measure the pKa of protein residues is 
nuclear magnetic resonance (NMR)-monitored pH titration
154-156
. Other 
techniques, such as isothermal titration calorimetry, enzymatic pH-activity 
profiles
157,158
, potentiometric titration and site-directed mutagenesis
159-161
 are 
less commonly used. However, all these techniques are time consuming and 
expensive. The size of proteins is also another limitation of experimental 
methods, particularly, NMR. Hence, validated or calibrated computational pKa 
predictions could be a useful way to estimate the pKa values, especially when 







5.1.2 Review of Previous Works 
The standard pKa value of an ionizable amino acid residue can be determined 
in aqueous solution of the isolated form of this residue. The common term 
used in textbook for standard pKa is model pKa, which will be used throughout 
the rest of this thesis. This pKa value correlates with the standard-state Gibbs 
free energy (   ) as follows: 
                a (5.1) 
where   is ideal gas constant,                  ,  
   is temperature (in K) 
 In proteins, this pKa value of an amino acid could shift from its model value 
by an additional energy term when this residue is transferred from the solvent 
to the protein environment. This energy value is determined by the 
electrostatics and other energy terms of immediate surroundings or 
microenvironment of the residue. Several approaches have been used to 
predict pKa, namely (1) macroscopic approaches, (2) microscopic approaches, 
and (3) empirical approaches. 
(1) Macroscopic approaches 
The transferred energy in macroscopic approaches can be directly calculated 
from the macroscopic electrostatics equations or Poisson-Boltzmann equation 
(PBE). Techniques classified under macroscopic approaches include PBE
163-
166
, PBE and conformational flexibility
167,168
, or Generalized Born
169-171
 





hydrogen-bonding and desolvation effects
172
 and overestimation the intra-
protein charge–charge interactions173,174 in calculating pKa shifts. 
(2) Microscopic approaches 
Microscopic approaches quantify all interactions at the atomic resolution. 
These approaches do not include any macroscopic physical features. These are 
the most desirable approaches because of their accuracy. However, their 
disadvantages are intensive computational complexity and time requirement. 
In these approaches, the quantities of electrostatic, and other physical 
interactions can be obtained by solving the Schrodinger equation. However, 
the current computing power is not sufficient for exactly solving the equation, 
and hence, some levels of approximation are applied. Several methods are in 
this category, including, quantum mechanical/molecular mechanics (QM/MM) 
based methods
175-177
, molecular dynamics (MD) based methods
178-180
, or 
continuum solvent models from the microscopic description
181-185
. 
(3) Empirical approaches 
Empirical approaches use a statistical analysis over a large database of 
experimentally determined pKa values. This method has the advantage in 
speed; however, the physical meanings of the determinants contributing to the 





classified as empirical methods. Among these methods, PROPKA is the most 
widely used because of its small root-mean-square deviation (reported as less 
than 1 pH unit). 
Our pKa prediction method falls into this category. As this empirical method 





to predict ionizable amino acid residue types with sufficient number of 
experimentally available pKa values, particularly, ASP, GLU, HIS and LYS. 
The next section explained the definition of priority features which are used to 
predict the pKa. 
5.2 Residue Depth 
Atom/residue depth is a measurement of the atomic or residue distance to the 
nearest surface bulk water
188,189
. A water molecule is a bulk solvent if it is 
surrounded by more than three neighbour waters within a sphere of 4.2 Å 
radius. Depth has been shown to correlate with a various physical and 
chemical properties in protein structures, including structural stability
188
, 
hydrogen/deuterium amide proton exchange rates
188,190








activity and 3D structural model accuracy
193
. In the context of proteins, pKa 
values are correlated with their immediate environments and could differ from 
the model pKa values. We used depth and other features to predict these shifts 
by characterizing the environment of ionizable groups. 
In the next two sections, 5.3 and 5.4, two different methods to predict the pKa 
are explained in detail. 
5.3 DEPTH-based pKa Prediction 
The predicted pKa,    
    
, is computed as follows: 
   
         
               
            
                 
               





where     
      is the model pKa (Table 5.1). 
        are coefficients of the individual features. 














c0 c1 c2 c3 c4 c5 





ASP 3.8 -2.18 0.29 0.47 -0.61 0.16 -0.15 1.02 (112) 0.71 (15) 
GLU 4.5 -1.91 -0.1 0.79 -0.19 0.26 -0.09 0.83 (125) 1.07 (15) 
HIS 6.5 3.13 -0.04 -0.54 0.28 -1.12 -0.83 1.14 (60) 1.26 (15) 
LYS 10.5 4.22 -0.21 -0.19 -0.01 -7.65 -1.81 0.86 (70) 0.8 (15) 
Total        0.94 (367) 0.96 (60) 




5.3.1 Features Constructing the DEPTH Model 
We used the following features to describe the environment, namely (1) depth, 
(2) electrostatic energy, (3) number of hydrogen bond, and (4) solvent 
accessible surface area. 
(1) Depth 
To accurately describe the solvent effects on an ionizable group, two 
complementary measures of depth are used in our predictor, particularly, 
average depth of main chain atoms (       ), and average depth of polar side 
chain atoms (            ) 
(2) Electrostatic energy (   ): 
All hydrogen atoms were explicitly added using the program Reduce
194
 for the 
electrostatics energy calculation. This energy term is calculated as follows: 
     ∑ ∑
      
   
           (5.3) 
where:    is the partial charge of an atom   in a residue  . 
    is the partial charge on an atom   in a residue    of the surrounding 
microenvironments (within a cut-off distance of 12 Å from the atom  ). 
     is the atomic distance between   and   atoms. 
We assumed that all acidic groups of ASP and GLU residues were 
deprotonated, whereas the basic groups of HIS and LYS residues were 








(3) Hydrogen Bond (  ):  
If the distance between donor-acceptor atom pairs was less than 3.5 Å and the 
donor-acceptor-acceptor antecedent angle was greater or equal to 100°
196,197
, 
the bond was identified as a hydrogen bond. 
(4) Solvent accessible surface area: 
The Shrake–Rupley algorithm198 was used to compute solvent accessible 
surface area of side chain atoms (     ). 
5.3.2 Dataset of experimental values of pKa used in DEPTH 
Prediction 
The coefficients        of separate amino acid reside types in equation 5.2 
were obtained by optimizing the predictions on the training set. The number of 
training residues for ASP, GLU, LYS and HIS are 112, 125, 70 and 60 
respectively (Table 5.2). The prediction formula was then tested on a set of 15 
residues for each amino acid type (Table 5.2 and Table 5.3). The data on 
testing and training sets did not overlap with each other. 
In the cases where the pKas were determined for mutant residues of proteins, 
to construct homology models we used the mutate_residue command of 
MODELLER
40
. In the cases where more than one alternative conformation for 
residues were reported, the first listed conformation was always chosen. 
  




Table 5.2: Listing of experimentally determined pKa values of ionizable 
residues and their sources. 367 of the values are used for training (number 1 in 
bracket at Method (set) column) of the predictor, and 60 are used on testing 















   




   
    
 
Error = 
(   
    
 
     
   
) 
The apo E2 
199
 1LE2 69 (A) LYS 10.1 X-ray (1) 10.59 0.49 
The apo E2 
199
 1LE2 72 (A) LYS 10 X-ray (1)  9.72 -0.28 
The apo E2 
199
 1LE2 75 (A) LYS 10 X-ray (1) 9.99 -0.01 
The apo E2 
199
 1LE2 95 (A) LYS 10.2 X-ray (1) 10.4 0.2 
The apo E2 
199
 1LE2 143 (A) LYS 9.4 X-ray (1) 9.43 0.03 
The apo E2 
199
 1LE2 146 (A) LYS 9.9 X-ray (2) 9.89 -0.01 
The apo E2 
199
 1LE2 157 (A) LYS 10.9 X-ray (1) 10.77 -0.13 
The apo E3 
200
 1NFN 69 (A) LYS 10.4 X-ray (1) 10.38 -0.02 
The apo E3 
200
 1NFN 72 (A) LYS 10 X-ray (1) 9.93 -0.07 
The apo E3 
200
 1NFN 75 (A) LYS 10.1 X-ray (1) 10.4 0.3 
The apo E3 
200
 1NFN 95 (A) LYS 10.1 X-ray (1) 10.4 0.3 
The apo E3 
200
 1NFN 143 (A) LYS 9.5 X-ray (2) 9.88 0.38 
The apo E3 
200
 1NFN 146 (A) LYS 9.2 X-ray (2) 9.81 0.61 
The apo E3 
200
 1NFN 157 (A) LYS 11.1 X-ray (1) 10.7 -0.4 
The apo E4 
199
 1GS9 69 (A) LYS 10.1 X-ray (1) 10.32 0.22 
The apo E4 
199
 1GS9 72 (A) LYS 10 X-ray (1) 10.23 0.23 
The apo E4 
199
 1GS9 75 (A) LYS 10.1 X-ray (1) 10.06 -0.04 
The apo E4 
199
 1GS9 95 (A) LYS 10.1 X-ray (1) 10.36 0.26 
The apo E4 
199
 1GS9 143 (A) LYS 9.9 X-ray (1) 9.73 -0.17 
The apo E4 
199
 1GS9 146 (A) LYS 9.4 X-ray (2) 9.83 0.43 
The apo E4 
199























 1RQL 53 (A) LYS 9.3 X-ray (1) 9.06 -0.24 
Barnase 
205
 1A2P 8 (A) ASP 3.3 X-ray (1) 2.67 -0.63 
Barnase 
205
 1A2P 12 (A) ASP 3.8 X-ray (1) 3.39 -0.41 
Barnase 
206
 1A2P 18 (A) HIS 7.73 X-ray (1) 6.87 -0.86 
Barnase 
205
 1A2P 22 (A) ASP 3.3 X-ray (1) 3.19 -0.11 
Barnase 
205
 1A2P 29 (A) GLU 3.75 X-ray (1) 3.87 0.12 
Barnase 
205
 1A2P 44 (A) ASP 3.35 X-ray (1) 3.71 0.36 
Barnase 
205
 1A2P 54 (A) ASP 2.2 X-ray (1) 3.14 0.94 
Barnase 
205
 1A2P 60 (A) GLU 3.2 X-ray (1) 4.31 1.11 
Barnase 
205
 1A2P 73 (A) GLU 2.2 X-ray (1) 4.14 1.94 
Barnase 
205
 1A2P 75 (A) ASP 3.1 X-ray (1) 5.06 1.96 
Barnase 
205
 1A2P 86 (A) ASP 4.2 X-ray (1) 4.12 -0.08 
Barnase 
205
 1A2P 93 (A) ASP 2 X-ray (1) 2.18 0.18 
Barnase 
205
 1A2P 101 (A) ASP 2 X-ray (1) 1.9 -0.1 






 1A2P 102 (A) HIS 6.3 X-ray (1) 6.69 0.39 
B1 domain 
of protein G 
207
 1PGB 4 (A) LYS 11 X-ray (1) 10.63 -0.37 
B1 domain 
of protein G 
207
 1PGB 10 (A) LYS 11 X-ray (1) 10.78 -0.22 
B1 domain 
of protein G 
207
 1PGB 13 (A) LYS 11 X-ray (1) 10.67 -0.33 
B1 domain 
of protein G 
207
 1PGB 15 (A) GLU 4.4 X-ray (1) 4.16 -0.24 
B1 domain 
of protein G 
207
 1PGB 19 (A) GLU 3.7 X-ray (1) 4.28 0.58 
B1 domain 
of protein G 
207
 1PGB 22 (A) ASP 2.9 X-ray (2) 2.98 0.08 
B1 domain 
of protein G 
207
 1PGB 27 (A) GLU 4.5 X-ray (2) 3.76 -0.74 
B1 domain 
of protein G 
207
 1PGB 28 (A) LYS 10.9 X-ray (2) 10.53 -0.37 
B1 domain 
of protein G 
207
 1PGB 36 (A) ASP 3.8 X-ray (2) 3.92 0.12 
B1 domain 
of protein G 
207
 1PGB 40 (A) ASP 4 X-ray (1) 3.89 -0.11 
B1 domain 
of protein G 
207
 1PGB 42 (A) GLU 4.4 X-ray (1) 4.29 -0.11 
B1 domain 
of protein G 
207
 1PGB 46 (A) ASP 3.6 X-ray (1) 2.87 -0.73 
B1 domain 
of protein G 
207
 1PGB 47 (A) ASP 3.4 X-ray (2) 3.26 -0.14 
B1 domain 
of protein G 
207
 1PGB 56 (A) GLU 4 X-ray (1) 4.51 0.51 
B2 domain 
of protein G 
207
 1IGD 9 (A) LYS 11 X-ray (1) 10.57 -0.43 
B2 domain 
of protein G 
207
 1IGD 15 (A) LYS 11 X-ray (1) 10.96 -0.04 
B2 domain 
of protein G 
207
 1IGD 18 (A) LYS 11 X-ray (1) 10.81 -0.19 
B2 domain 
of protein G 
207
 1IGD 20 (A) GLU 4.3 X-ray (1) 4.22 -0.08 
B2 domain 
of protein G 
207
 1IGD 24 (A) LYS 10.7 X-ray (1) 10.65 -0.05 
B2 domain 
of protein G 
207
 1IGD 27 (A) ASP 2.9 X-ray (1) 2.5 -0.4 
B2 domain 
of protein G 
207
 1IGD 29 (A) GLU 4.2 X-ray (1) 4.08 -0.12 
B2 domain 
of protein G 
207
 1IGD 32 (A) GLU 4.6 X-ray (1) 3.66 -0.94 
B2 domain 
of protein G 
207
 1IGD 33 (A) LYS 11 X-ray (1) 10.73 -0.27 
B2 domain 
of protein G 
207
 1IGD 41 (A) ASP 3.9 X-ray (1) 3.28 -0.62 
B2 domain 
of protein G 
207
 1IGD 45 (A) ASP 4 X-ray (1) 3.86 -0.14 
B2 domain 
of protein G 
207
 1IGD 51 (A) ASP 3.6 X-ray (1) 2.28 -1.32 
B2 domain 
of protein G 
207
 1IGD 52 (A) ASP 3.4 X-ray (1) 2.71 -0.69 
B2 domain 
of protein G 
207
 1IGD 61 (A) GLU 4.2 X-ray (1) 4.75 0.55 
Bull 
208
 2BUS 9 (A) GLU 4.3 NMR (1) 4.38 0.08 










































































































 1IG5 72 (A) LYS 11.3 X-ray (1) 10.8 -0.5 
Cardiotoxin 
211
 1KXI 4 (A) HIS 5.6 X-ray (1) 6.5 0.9 
















 1KXI 59 (A) ASP 2.3 X-ray (1) 3.4 1.1 
CD2d1 
212
 1HNG 2 (A) ASP 3.5 X-ray (1) 3.22 -0.28 
CD2d1 
212
 1HNG 25 (A) ASP 3.53 X-ray (1) 3.84 0.31 
CD2d1 
212
 1HNG 26 (A) ASP 3.58 X-ray (1) 3.97 0.39 
CD2d1 
212
 1HNG 28 (A) ASP 3.57 X-ray (1) 4.07 0.5 
CD2d1 
212
 1HNG 29 (A) GLU 4.51 X-ray (1) 3.81 -0.7 
CD2d1 
212
 1HNG 33 (A) GLU 4.2 X-ray (1) 3.95 -0.25 
CD2d1 
212
 1HNG 41 (A) GLU 6.7 X-ray (2) 4.26 -2.44 
CD2d1 
212
 1HNG 56 (A) GLU 3.95 X-ray (1) 3.87 -0.08 
CD2d1 
212
 1HNG 62 (A) ASP 4.18 X-ray (1) 4.49 0.31 
CD2d1 
212
 1HNG 71 (A) ASP 3.2 X-ray (1) 3.87 0.67 
CD2d1 
212
 1HNG 72 (A) ASP 4.14 X-ray (1) 3.3 -0.84 
CD2d1 
212
 1HNG 94 (A) ASP 3.83 X-ray (1) 4.45 0.62 
CD2d1 
212








 2TGA 57 (A) HIS 7.3 X-ray (1) 5.62 -1.68 
Cyclophilin 
214
 2CPL 54 (A) HIS 4.2 X-ray (1) 4.9 0.7 
Cyclophilin 
214
 2CPL 70 (A) HIS 5.8 X-ray (1) 5.87 0.07 
Cyclophilin 
214
 2CPL 92 (A) HIS 4.2 X-ray (1) 3.92 -0.28 
Cyclophilin 
214










































 1EGF 51 (A) GLU 4 NMR (1) 4.48 0.48 






 1FKS 25 (A) HIS 3.6 X-ray (1) 6.25 2.65 
FKBP 
214
 1FKS 87 (A) HIS 6.5 X-ray (1) 6.7 0.2 
FKBP 
214


























































































 1DE3 91 (A) ASP 3 NMR (1) 3.43 0.43 






























































































 4LZT 35 (A) GLU 6.2 X-ray (2) 4.24 -1.96 
















































 4LZT 119 (A) ASP 3.2 X-ray (1) 2.65 -0.55 
Hirudin 
219
 1HIC 5 (A) ASP 4.3 NMR (1) 4.21 -0.09 
Hirudin 
219
 1HIC 8 (A) GLU 4.3 NMR (1) 4.08 -0.22 
Hirudin 
219
 1HIC 17 (A) GLU 3.8 NMR (1) 4.12 0.32 
Hirudin 
219
 1HIC 35 (A) GLU 4.3 NMR (1) 4.29 -0.01 
Hirudin 
219














































 1ERU 20 (A) ASP 3.8 X-ray (1) 3.87 0.07 



































































































 1ERT 43 (A) HIS 5.5 X-ray (1) 6.77 1.27 
Human 
223
 1ERT 47 (A) GLU 4.1 X-ray (1) 4.08 -0.02 




























































































































 1A6K 36 (A) HIS 8 X-ray (1) 6.28 -1.72 




























































































 4PTI 49 (A) GLU 3.91 X-ray (1) 4.24 0.33 





































































































































 2RN2 127 (A) HIS 7.9 X-ray (2) 6.98 -0.92 



































 3RN3 2 (A) GLU 2.6 X-ray (2) 3.9 1.3 
Ribonucleas
e A 
















































































 1RGG 54 (A) GLU 3.42 X-ray (1) 3.42 0 






































































































 3BDC 20 (A) 
GLU
* 






 3BDC 20 (A) 
LYS
* 
10.4 X-ray (1) 8.74 -1.66 
Staph 
149
 3BDC 21 (A) ASP 6.5 X-ray (1) 3.79 -2.71 












 3BDC 23 (A) 
GLU
* 






 3BDC 23 (A) 
LYS
* 






 3BDC 34 (A) 
GLU
* 






 3BDC 36 (A) 
GLU
* 






 3BDC 37 (A) 
GLU
* 






 3BDC 37 (A) 
LYS
* 






 3BDC 39 (A) 
GLU
* 






 3BDC 39 (A) 
LYS
* 












 3BDC 41 (A) 
GLU
* 






 3BDC 41 (A) 
LYS
* 


















 3BDC 57 (A) GLU 3.5 X-ray (1) 4.29 0.79 









 3BDC 58 (A) 
GLU
* 






 3BDC 58 (A) 
LYS
* 






 3BDC 62 (A) 
GLU
* 


















 3BDC 74 (A) 
GLU
* 
























 3BDC 90 (A) 
LYS
* 






 3BDC 90 (A) 
GLU
* 






 3BDC 91 (A) 
LYS
* 












 3BDC 99 (A) 
GLU
* 





 3BDC 100 (A) 
GLU
* 
7.6 X-ray (1) 8.33 0.73 










 3BDC 100 (A) 
LYS
* 












 3BDC 103 (A) 
GLU
* 






 3BDC 109 (A) 
GLU
* 






 3BDC 109 (A) 
LYS
* 






 3BDC 118 (A) 
LYS
* 






 3BDC 118 (A) 
GLU
* 












 3BDC 125 (A) 
GLU
* 


































 3ERQ 25 (A) LYS 6.2 X-ray (1) 7.53 1.33 




























































































 1TQO 92 (A) GLU 9 X-ray (1) 8.76 -0.24 
Staph 
236
 4HMI 99 (A) LYS 6.5 X-ray (1) 7.98 1.48 




































































































 1PPF 29 (A) LYS 11.1 X-ray (1) 10.85 -0.25 



















































































































 1XNB 119 (A) ASP 3.2 X-ray (1) 2.66 -0.54 



















 1XNB 172 (A) GLU 6.7 X-ray (1) 4.8 -1.9 
*
 indicates a mutant residues, modeled using MODELLER. 
  







Table 5.3: Benchmarking of pKa prediction using DEPTH and other methods on a testing set of 60 ionizable residues. 
PDB 
Code 
Residue    
   
 
Error =    
   
 –    






PROPKA3.0 GDDM MM-SCP EGAD MCCE QM/MM DEPTH 
3RN3 ASP14 -2.2 1.2 1.9 0.4 0.4 0.6 NA 1.2 NA 0.1 
4LZT ASP87 -1.9 NA 1.1 1.4 0.9 1.1 0.8 -0.9 NA 1.2 
1PPF ASP27 -1.8 2.0 2.4 0.5 1.2 1.7 0.8 1.1 -0.3 0.2 
1XNB ASP11 -1.5 NA 1.4 0.4 0.7 NA 1.1 NA NA 0.3 
1BEO ASP21 -1.5 NA 0.4 -1.0 NA NA NA 2.6 0.0 -0.2 
4LZT ASP18 -1.3 NA 0.5 0.8 1.1 0.8 0.8 0.3 NA 0.5 
1XNB ASP106 -1.3 NA 0.1 1.1 0.8 NA 0.8 NA NA 1.7 
1PGA ASP22 -1.1 NA 0.7 -0.2 1.3 0.0 0.6 -0.7 NA 0.2 
3RN3 ASP121 -0.9 1.9 1.9 0.0 -0.9 0.8 NA 0.1 NA 0.7 
1A2P ASP75 -0.9 NA 1.2 1.0 -0.7 NA 3.2 1.4 NA 2.3 
2RN2 ASP94 -0.8 NA 1.1 -0.4 -0.5 0.3 NA 0.6 NA -0.6 
1PGA ASP47 -0.6 NA 0.5 -1.2 0.5 -0.8 -0.1 -1.1 NA -0.2 
3RN3 ASP53 -0.3 NA 1.3 0.3 -0.2 0.3 NA 0.0 NA 0.3 
4LZT ASP52 -0.3 2.4 2.3 -0.1 1.1 -0.2 -0.1 0.2 NA 0.1 
1PGA ASP36 -0.2 NA 0.8 0.3 0.1 0.6 0.7 1.2 NA 0.0 







2TRX ASP20 -0.2 NA 0.2 0.2 NA NA NA NA NA -0.1 
1DE3 ASP59 0.1 NA -0.2 -0.4 0.7 NA -1.7 NA NA -0.2 
1DE3 ASP57 0.3 NA -0.4 -0.3 -0.8 NA -0.9 NA NA -0.3 
2RN2 ASP10 2.1 NA 0.6 1.0 NA -0.2 NA 4.3 NA -1.4 
2TRX ASP26 4.1 NA -0.4 -1.3 -2.2 NA NA NA NA -0.5 
RMSD 
(N) 
  1.9 (4) 1.2 (20) 0.7 (20) 1.0 (17) 0.8 (12) 1.2 (13) 1.6 (14) 0.2 (2) 0.8 (20) 
MAD   1.9 1.0 0.6 0.8 0.6 1.0 1.0 0.3 0.6 




Residue    
   
 
Error =    
   
 –    






PROPKA3.0 GDDM MM-SCP EGAD MCCE QM/MM DEPTH 
3RN3 GLU2 -1.8 NA -0.2 0.5 1.3 1.2 NA -1.3 NA 1.3 
4LZT GLU7 -1.5 2.1 1.5 1.1 0.4 0.6 -0.3 0.6 -0.2 1.2 
1PPF GLU19 -1.2 NA 0.9 2.2 1.0 0.9 0.5 -1.6 -0.5 0.9 
2RN2 GLU57 -1.2 NA 1.4 0.3 1.8 -0.5 NA -0.7 NA 0.5 
1A2P GLU60 -1.2 1.6 1.9 0.2 -0.1 NA 0.0 -1.4 NA 1.1 







3RN3 GLU111 -0.9 NA 1.4 1.2 0.5 0.9 NA 0.4 NA 0.5 
2RN2 GLU129 -0.8 NA 0.3 -0.3 -0.2 -0.6 NA -0.8 NA 0.2 
2RN2 GLU61 -0.5 NA 1.0 -0.1 -0.4 -0.3 NA -1.0 NA -0.1 
3RN3 GLU9 -0.4 2.0 1.7 1.0 -0.2 0.6 NA 1.4 NA 0.1 
2BCA GLU26 -0.3 NA 0.7 1.1 NA NA NA -1.4 NA 0.1 
1PPF GLU10 -0.3 NA 1.0 0.3 -0.3 0.2 0.0 -0.6 0.2 0.2 
2RN2 GLU119 -0.3 1.6 1.9 -0.6 -0.7 -0.3 NA -1.0 NA 0.1 
1PGA GLU27 0.1 NA 1.2 -1.7 -0.8 -1.4 -0.2 -0.7 NA -0.8 
1PPF GLU43 0.4 NA -0.1 -0.2 -0.5 -0.4 0.6 -0.3 -0.3 -0.6 
1DE3 GLU96 0.7 0.0 1.7 2.4 -0.8 NA -1.0 NA NA 1.1 
1ANS GLU20 1 NA -0.3 -0.8 -1.1 NA NA NA NA -1.0 
1RGA GLU28 1.5 NA -0.3 -1.6 -1.6 NA -0.2 NA NA -1.4 
4LZT GLU35 1.8 NA 0.0 0.2 -1.0 0.1 0.0 0.0 NA -2.0 
1HNG GLU41 2.3 NA 0.0 -1.1 NA NA -3.3 -0.9 NA -2.5 






















MAD   1.5 0.9 0.9 0.8 0.6 0.6 0.9 0.3 0.9 
MAX   2.1 1.9 2.4 2.0 1.4 3.3 1.6 0.5 2.5 










Residue    
   
 
Error =    
   
 –    






PROPKA3.0 GDDM MM-SCP EGAD MCCE QM/MM DEPTH 
2SNM LYS66 -4.1 NA 1.0 0.6 1.5 NA NA NA NA 1.0 
1L54 LYS102 -3.9 2.5 3.0 0.2 1.8 NA NA NA NA 1.9 
1MUT LYS39 -2.1 2.5 2.4 2.0 NA NA NA NA NA 2.6 
1NFN LYS146 -1.3 NA 0.5 1.0 NA NA NA 0.2 NA 0.5 
1FEZ LYS53 -1.2 1.4 3.0 -1.0 NA NA NA NA NA -0.3 
1GS9 LYS146 -1.1 NA 0.3 0.9 NA NA NA NA NA 0.3 
1LE2 LYS143 -1.1 NA 0.9 0.2 NA NA NA NA NA -0.2 
1NFN LYS143 -1.0 NA 0.7 0.9 NA NA NA -1.4 NA 0.3 
1NZP LYS312 -1.0 1.0 1.7 1.4 NA NA NA NA NA -0.3 
1GS9 LYS143 -0.6 NA 0.3 0.5 NA NA NA NA NA -0.4 
1LE2 LYS146 -0.6 NA 0.1 0.3 NA NA NA NA NA -0.2 
1PPF LYS34 -0.4 NA 0.2 0.0 NA 0.9 NA -2.9 NA 0.8 
4LZT LYS33 -0.1 NA -0.3 -0.5 0.0 1.0 NA -0.6 NA 0.3 
2BCA LYS41 0.3 NA -0.1 -0.5 0.2 -0.3 NA -0.2 NA -0.3 
4LZT LYS96 0.3 NA -0.2 -0.7 -0.2 -0.1 NA 0.5 NA -0.8 







1PGA LYS28 0.4 NA -0.2 0.2 0.3 0.5 NA 0.8 NA -0.3 
2BCA LYS16 0.4 NA 0.3 -0.7 0.6 -0.2 NA 0.3 NA 0.2 
1PPF LYS55 0.6 NA -0.4 -0.8 NA -0.6 NA -0.9 NA -0.7 
2BCA LYS7 0.7 NA 0.2 -0.7 0.1 -0.3 NA -0.3 NA -0.6 
2BCA LYS55 1.3 NA 0.0 -1.3 -0.4 -0.6 NA -0.1 NA -1.3 
RMSD 
(N) 
  2.0 (4) 1.2 (20) 0.9 (20) 0.8 (9) 0.6 (9) NA 1.1 (11) NA 0.9 (20) 
MAD   1.9 0.8 0.7 0.6 0.5 NA 0.7 NA 0.7 




Residue    
   
 
Error =    
   
 –    






PROPKA3.0 GDDM MM-SCP EGAD MCCE QM/MM DEPTH 
3EBX HIS6 -3.5 NA -1.1 2.9 3.2 NA NA NA NA 2.7 
3SSI HIS43 -3.1 NA 0.0 2.9 2.5 NA NA NA NA 0.9 
1STN HIS121 -1 1.9 2.4 1.1 2.2 NA 2.8 NA NA 1.0 
4LZT HIS15 -0.9 2.2 2.8 1.2 0.7 0.3 1.3 1.1 NA 0.8 
1ERT HIS43 -0.8 NA 1.0 0.3 1.2 NA NA NA NA 1.2 
1DE3 HIS137 -0.5 2.6 1.8 -0.9 -0.8 NA 1.2 NA NA -0.8 







3RN3 HIS48 -0.2 1.1 5.1 -0.4 0.3 0.3 NA 2.7 NA -1.6 
3RN3 HIS119 0.2 NA -0.7 -0.1 0.9 -0.3 NA -1.1 NA -0.5 
3RN3 HIS12 -0.3 NA 0.8 -2.3 0.0 -0.2 NA -1.8 NA -1.2 
1DE3 HIS104 0.2 0.7 2.1 -0.1 -0.6 NA 1.1 NA NA 0.2 
1DE3 HIS36 0.5 NA 0.2 -0.3 -0.2 NA 1.1 NA NA -0.7 
2RN2 HIS62 0.7 NA 0.0 -0.3 -0.1 0.0 0.0 -0.3 NA -0.2 
2RN2 HIS124 0.8 -1.6 -1.9 -0.8 -0.5 -1.3 NA -2.6 NA -0.2 
1DE3 HIS50 1.4 2.1 1.7 -3.9 -1.0 NA 0.7 NA NA -1.3 
1RGA HIS92 1.5 NA -0.3 -3.4 -1.1 -0.4 NA -0.7 NA -1.3 
1RGA HIS40 1.6 NA 0.0 -2.5 -1.5 -0.5 NA 1.1 NA -1.4 
2RN2 HIS127 1.6 NA 0.0 -0.5 -0.5 -0.3 NA -0.9 NA -0.7 
1DG9 HIS66 2 NA 0.7 -1.7 -0.9 NA NA NA NA -1.4 
2LZM HIS31 2.8 -1.3 -1.9 -2.5 -1.9 NA 1.1 NA NA -3.0 
1DG9 HIS72 2.9 NA 0.3 -3.5 -2.2 NA NA NA NA -3.3 
RMSD 
(N) 
  1.9 (8) 1.8 (20) 2 (20) 1.4 (20) 0.5 (9) 1.4 (8) 1.6 (9) NA 1.5 (20) 
MAD   1.8 1.3 1.6 1.1 0.4 1.2 1.4 NA 1.2 
MAX   2.4 5.1 3.9 3.2 1.3 2.8 2.7 NA 3.3 
Total   1.9 (21) 1.4 (80) 1.3 (80) 1.1 (64) 0.7 (43) 1.2 1.4 (50) 0.3 (6) 1.1 (80) 












  1.8 1.0 0.9 0.8 0.5 0.9 1.0 0.3 0.8 
TotalM
AX 
  2.5 5.1 3.9 3.2 1.7 3.3 4.3 0.5 3.3 
Note: In some cases, we have used structures of the same protein under different PDB code than those as listed in 
250
. They are: 2TRZ 
= 1 ERT, 2BCA = 1IG5, 1PGA = 1PGB, 1FEZ = 1RQL, 1NZP = 1XSN, 3SSI = 2 SIC, 1STN = 1STY.  
RMSD (Root mean squared deviations), MAD (mean absolute deviation), MAX (maximum absolute deviation) for predicted pKa 
values are shown for each residue type. The number of pKa values used to calculate RMSD, MAD, MAX is in parentheses. 
  




5.3.3 Results and Benchmarking 
A large number of features were arranged in a linear combination in an 
attempt to describe microenvironment of a residue as shown in equation 5.2 
(Table 5.4). Among these features, depth of polar side chain atoms and depth 
of main chain atoms were the most informative of the environmental features. 
Using the training set of 367 residues with experimentally determined pKa 
values, the coefficients of the linear combination of microenvironment 
features (equation (5.2) were optimized (Table 5.1). These optimized values 
were applied to make the pKa predictions on 60 residues on the testing set 
(Table 5.2). On average, RMSDs of DEPTH-based pKa predictions were 0.96 
pH units in comparison with that of the experimentally determined values. The 
best performance of pKa prediction by DEPTH-based method is for ASP with 
the RMSD of 0.71 pH units, whereas the worst performance is for HIS with 
the RMSD of 1.26 pH units. 
We benchmarked our predictions with those made by other methods, including 
(i) Molecular dynamics/ generalized-Born/thermodynamic integration 









, (v) Egad! A 
Genetic Algorithm for Protein Design! (EGAD)
252
, (vi) Monte Carlo sampling 
with continuum electrostatics (MCCE)
253
 and a Quantum mechanics/molecular 
mechanics (QM/MM) method
175
 (Table 5.3). The predicted pKa values from 
the methods listed earlier in the text were obtained from literature
250
, except 
PROPKA. PROPKA 3.0 using default parameters was run over the web server 
(http://propka.ki.ku.dk/). 




In terms of the predicted pKa error, our predictions were significantly better 
(using a Wilcoxon paired sign rank test at 95% confidence) than the 
predictions of EGAD, MD/GB/TI, and GDDM (Table 5.3). Our results were 
on par with the PROPKA 3.0 and MCCE methods. Only pKa predicted values 
from QM/MM (0.30 pH units over five predictions) and MM-SCP (0.70 pH 
units over 43 predictions) methods have lower errors than our method (0.96 
pH units). Though the MM-SCP method is statistically superior to our simple 
empirical method, we are closer to the experimentally determined value in 18 
and worse in 21 of the 43 common predictions. In four cases the results were 
identical between our method and MM-SCP. 
  




Table 5.4: Physical features tested (individually) for correlation with pKa. 
Number Feature 
1 Main chain atom depth 
2 Polar main chain atom depth 
3 Side chain atom depth 
4 Polar side chain atom depth 
5 Residue depth 
6 Polar residue depth  
7 Number of neighbor atoms 
8 Main chain atom depth of neighbor atoms 
9 Polar main chain atom depth of neighbor atoms 
10 Side chain atom depth of neighbor atoms 
11 Polar side chain atom depth of neighbor atoms 
12 Residue depth of neighbor atoms 
13 Polar residue depth of neighbor atoms 
14 Number of neighbor charged atoms 
15 Number of hydrogen bonds 
16 
Electrostatic energy between the ionizable groups and their 
environments if ionizable groups in charged 
17 
Electrostatic energy between the ionizable groups and their 
environments if ionizable groups in neutral 
18 Delta of two above electrostatic energies 
19 All atom solvent accessible surface area 
20 Percentage all atom solvent accessible surface area 
21 Non-polar side chain solvent accessible surface area 
22 Percentage non-polar side chain solvent accessible surface area 
23 Polar side chain solvent accessible surface area 
24 Percentage polar side chain solvent accessible surface area 
25 Side chain solvent accessible surface area 
26 Percentage side chain solvent accessible surface area 
27 Main chain solvent accessible surface area 
28 Percentage main chain solvent accessible surface area 
29 Chi torsion angle of ionizable groups 
30 B factor of ionizable groups 
31 B factor of ionizable group neighbor 
 
Table 5.5: Optimized coefficients of linear recombination for the different 




c1 c2 c3 c4 c5 c6 c0 
ASP 3.8 0.22 -0.07 -0.21 0.10 -0.02 0.66 -0.88 
GLU 4.5 0.00 0.06 -0.01 0.16 0.06 0.14 -0.50 
HIS 6.5 -0.20 -0.05 0.06 1.76 -1.14 0.44 1.84 
LYS 10.5 -0.02 0.01 -0.01 0.83 0.66 0.69 -0.15 




5.4 Meta-algorithm DEMM for pKa Prediction 
We discovered that our predictor synergizes (a modest correlation coefficient 
of 0.66) with another physics-based method of MM-SCP (Figure 5.1). Hence a 
meta-predictor DEMM combining these two methods are constructed. MM-
SCP attributes the shift of pKa from the model value solely to electrostatic 
interaction among ionizable groups in proteins. This method improved the 
calculation of electrostatic interactions by explicitly considering the screening 
of the Coulombic potential. Contributions to the Coulombic screening come 
from the amino acid residues in the surrounding microenvironment of the 
ionizable group. To model this screening effect the MM-SCP method uses the 
hydrophobicity and accessibilities of chemical groups constituting the amino 
acids. 
.  
Figure 5.1: Complementarity between DEPTH and MMSCP in pKa 
prediction.  




5.4.1 Improvement in the Electrostatic Calculation. 
In DEMM, we made a change in the calculation of the electrostatic term, 
which improved the pKa calculation according to the formula  
     ∑ ∑
       
   
           (5.4) 
where     is the difference in partial charge of an atom   in a residue   
between its protonated/deprotonated forms.  
       and     are as in section 5.3.1 
If    is an ionizable residue, the partial charge    was chosen to correspond to 
the protonation state of residue    at a pH equivalent to the model pKa of 
residue  . 
The predicted pKa,    
    
is computed as 
   
         
               
            
                
                
           
           
             (5.5) 
where    
      and    
       are the model pKa and pKa predicted by MM-
SCP method respectively. 
        are coefficients of the individual features. 
The values of the coefficients were optimized over a training set of residues. 
5.4.2 Dataset of experimental values of pKa used in DEMM 
Prediction 
A dataset of 222 amino acid residues with their pKa values experimentally 
measured
254
 were used to train (175) and test (47) our algorithm. The entire 




dataset consists of 58 ASP, 57 GLU, 71 HIS and 36 LYS residues from 54 X-
ray structures (resolution ranging from 1.2Å to 3.2Å). 
5.4.3 Results and Performance Benchmark 
The coefficients of the linear combination,        (equation 5.5) for each of 
the residue types ASP, GLU, HIS and LYS were optimized separately. On the 
training dataset of 175 residues a conjugate gradient optimization was done 
(Table 5.5). First, the coefficient of the MM-SCP method contribution,   , was 
set to 0.5. The coefficients of the features contributing to original DEPTH 
algorithm,        were taken as one half of their values from the original 
algorithm
88
 in section 5.3. The optimization was performed until convergence 
was reached with a tolerance value of     . 
Our prediction method was tested on a set of 47 residues. The error rates for 
different amino acids were slightly different from each other. Our predictions 
for LYS were closest to the experimentally determined values (Mean error = 
0.33 pH units, RMSD = 0.40 pH units), whereas predictions for HIS were the 
farthest (Mean error = 0.65 pH units, RMSD = 0.88 pH units). Overall, the 
prediction error is about 0.49 pH units (or RMSD 0.67 pH units) (Table 5.6). 
Using a Wilcoxon paired sign rank test, our method was shown to be 
statistically significantly superior to its individual component methods, 
particularly DEPTH and MM-SCP (Table 5.6). 
Detailed information on the pKa predictions for the 222 ionizable residues of 
the training and testing set are shown in Table 5.7. 
  




5.5 Case Study and Web-server 
5.5.1 Case Study 
The residue ASP 148 E-coli ribonuclease H (PDB ID: 2RN2) (Figure 5.2) is 
an example of complementarity between pKa prediction by DEPTH and MM-
SCP. The experimental determined pKa value of this residue is 2. This residue 
has a polar side chain depth of 5.6 Å and 6 hydrogen bonding interactions. As 
depth and hydrogen bonding effect are not considered in MM-SCP, this 
method overpredicted the pKa value by 1.25 pH units. In the case DEPTH had 
a smaller error but underpredicted the value by -0.69 pH units. DEMM 
predicts a pKa of 1.84, only -0.16 pH units from the experimental value. There 
are improvement of 0.53 and 1.09 pH units in DEMM prediction over the 
DEPTH and MM-SCP methods, respectively. 
 
Figure 5.2: A ribbon representation of the ribonuclease H (PDB ID: 2RN2). 
The pKa predicted 148D residue is shown in green sticks. The four residues 
(46, 149-151) that make hydrogen bonds (cyan lines) with 148D are also 
shown in pink stick representation. The figure was generated using Chimera
42
. 




 Table 5.6: Performance benchmark of DEPTH, MMSCP and DEMM over 47 
ionizable groups on the testing set. The mean absolute errors of predictions by 
the different methods and the corresponding RMSD (in brackets) are recorded 
in pH units. The improvement is the difference between DEMM and the more 
accurate prediction between DEPTH and MM-SCP. 
*
 statistical significance 
5.5.2 Web-server 
The pKa prediction of ionizable amino acid residues is available with other 
prediction tools which use depth as a determinant feature. The server 
http://mspc.bii.a-star.edu.sg/depth is freely accessible with no login 
requirements. Either four-letter PDB code or protein structure in PDB format 
is acceptable in our server. The information about the program, as well as its 
parameters, is available at help pages. 
The results of the pKa prediction are pictorially viewed represented with figure 
legends. The results in tab-delimited format are also available for 
downloading. All results are stored up to 30 days. Users can download the 
standalone version of the pKa prediction program for local use. 
Residue type (N) DEPTH MM-SCP DEMM Improvement 
ASP (12) 0.72 (1.04) 0.67 (0.79) 0.53 (0.67) 0.14 (0.12) 
GLU (12) 0.37 (0.48) 0.45 (0.58) 0.37 (0.5) 0 (-0.02) 
HIS (15) 1.14 (1.45) 1.15 (1.54) 0.65 (0.88) 0.49 (0.57) 
LYS (7) 0.43 (0.53) 0.48 (0.66) 0.33 (0.4) 0.1 (0.13) 
Total (47) 0.71 (1.03) 0.73 (1.04) 0.49 (0.67) 0.22 (0.36) 
P-value (1-tailed) 0.000* 0.004*   
P-value (2-tailed) 0.001* 0.012*   




5.6 Chapter Summary and Discussions 
DEPTH-based pKa prediction method empirically describes the 
microenvironment using both physical and chemical features. MM-SCP pKa 
prediction method calculates the screened electrostatic interactions of 
ionizable groups by considering the hydrophobicity of the surrounding amino 
acid residues. These two methods complement each other. On the one hand 
DEPTH has considered both the residue environments using residue depth and 
a coarse treatment of the electrostatics within a radius of up to 12 Å. On the 
other hand, MM-SCP has sophisticated electrostatics, describing the screening 
effect in the 4.25 Å vicinity of an ionizable group. However, MMSCP uses 
only solvent accessible area to describe residue environment. 
The DEMM pKa prediction method integrated the two complementary 
methods, DEPTH and MM-SCP. Overall, DEMM has a mean error of 0.49 pH 
units and an RMSD of 0.67 pH units. This model improved the prediction of 
all four ionizable amino acid residue types, including ASP, GLU, HIS and 
LYS. One significant improvement is in the case of HIS, which is usually the 
most difficult to predict. With a deviation of 0.49 pH units from experimental 
values, it was better predicted than the previous methods. 
In comparison with other empirical models, quantum mechanics/molecular 
mechanics (QM/MM)
175
 method still remains as the most accurate pKa 
prediction method with an RMSD of 0.3 pH units. The high performance of 
QM/MM could be because of its flexibility and adaptive assignment of partial 
charge, as well as its explicit consideration of protein dynamics. However, the 
QM/MM approach is computationally expensive and not possible for large-




scale studies. In contrast, our empirical method is fast, relatively accurate and 
can readily be applied to proteins/protein complexes without a size limitation. 
One disadvantage of DEMM pKa prediction is the absence of pKa prediction 
of residues Cys, Tyr and Arg. This problem could be overcome when the 
number of the experimentally determined pKa values of those residues is 
sufficient to train our algorithm.  
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MM-SCP DEPTH DEMM 
1A2P ASP 12 3.65 0.56 -0.21 0.04 
1A2P ASP 22 3.3 0.45 0.22 -0.04 
1A2P ASP 44 3.35 0.66 0.46 0.18 
1A2P ASP 75 3.1 -0.36 1.85 -0.51 
1A2P ASP 8 3 0.81 -0.19 0.35 
1A2P ASP 86 4.2 -0.76 -0.57 -0.80 
1A2P GLU 29 3.75 0.32 0.29 0.07 
1A2P GLU 60 3.4 0.41 0.72 0.29 
1A2P HIS 102 6.3 -0.04 0.15 0.32 
1A2P HIS 18 7.9 -1.16 -1.42 -1.28 
1AZP ASP 16 2.89 1.08 0.56 0.52 
1AZP ASP 35 3.42 -0.20 -1.6 -0.55 
1AZP ASP 36 3.12 0.87 0.43 0.26 
1AZP ASP 49 3.55 -0.21 -0.73 -0.66 
1AZP ASP 56 3.35 -0.02 -0.51 -0.47 
1AZP GLU 11 4.19 -0.41 -0.39 -0.59 
1AZP GLU 12 4.41 -0.43 -0.33 -0.70 
1AZP GLU 14 4 -0.05 -0.01 -0.18 
1AZP GLU 47 4.21 0.02 -0.3 -0.26 
1AZP GLU 53 3.53 0.86 0.4 0.59 
1AZP GLU 62 3.99 0.73 0.21 0.30 
1AZP GLU 64 4.23 0.44 -0.08 0.01 
1BCX GLU 78 4 -0.54 1.19 -0.61 
1BEO ASP 21 2.49 0.26 -0.33 -0.03 
1BEO ASP 30 2.51 0.85 0.47 0.51 
1BEO ASP 72 2.61 0.86 0.81 0.62 
1BNZ ASP 16 2.11 1.28 2.1 1.21 
1BNZ ASP 35 2.16 0.59 1.13 0.52 
1BNZ ASP 50 2.96 0.40 0.7 0.09 
1BNZ GLU 11 3.78 -0.52 -0.01 -0.50 
1BNZ GLU 12 3.9 -0.21 0.42 -0.23 
1BNZ GLU 36 4.33 -0.52 -0.51 -0.67 
1BNZ GLU 48 3.45 0.73 0.53 0.40 
1BNZ GLU 54 3.01 0.23 0.83 0.13 
1BNZ GLU 60 3.82 0.31 0.28 0.11 
1BNZ ASP 35 2.67 0.95 0.62 0.52 
1BNZ ASP 50 3.55 0.27 0.11 -0.23 
1BNZ GLU 11 4.17 -0.25 -0.4 -0.51 
1BNZ GLU 12 4.33 -0.51 -0.01 -0.59 
1BNZ GLU 36 4.89 -0.32 -1.07 -0.78 
1BNZ GLU 48 4.03 0.37 -0.05 -0.05 
1BNZ GLU 54 3.56 0.37 0.28 -0.02 
1BNZ GLU 60 4.24 0.31 -0.14 -0.07 
1BTJ HIS 249 7.4 -1.78 -1.21 -0.73 




1DG9 HIS 66 8.29 -2.03 -1.87 -1.26 
1DIV ASP 23 3.05 0.21 0.65 -0.01 
1DIV ASP 8 2.99 0.99 0.56 0.43 
1DIV GLU 17 3.57 0.37 0.16 0.17 
1DIV GLU 38 4.04 0.30 -0.05 0.03 
1DIV GLU 48 4.21 0.41 -0.15 0.03 
1DIV GLU 54 4.21 -0.30 -0.16 -0.57 
1DUI HIS 64 7.17 -0.29 -0.25 0.15 
1ERT ASP 16 3.7 0.40 0.34 -0.01 
1ERT ASP 20 3.6 0.18 0.13 -0.25 
1ERT GLU 103 4.9 -0.43 -0.47 -0.68 
1ERT GLU 13 4.8 -0.31 -0.61 -0.58 
1ERT GLU 68 4.2 0.60 0.15 0.20 
1ERT GLU 88 3.9 0.08 0.18 -0.17 
1ERT HIS 43 5.5 0.37 1.32 1.21 
1FEZ LYS 53 9.3 0.35 -0.96 3.43 
1FNA ASP 67 4.18 -0.33 -1.21 -0.87 
1FNA ASP 80 3.4 0.87 0.32 0.15 
1FNA GLU 38 3.79 -0.02 0.13 -0.18 
1FNA GLU 47 3.94 -0.22 -0.07 -0.46 
1GS9 LYS 143 9.9 0.45 -0.28 -3.20 
1GS9 LYS 146 9.4 0.92 0.32 -2.65 
1GS9 LYS 157 10.9 -0.17 -0.42 -3.70 
1GS9 LYS 69 10.1 0.57 0.4 -2.88 
1GS9 LYS 72 10 0.40 0.5 -2.91 
1GS9 LYS 75 10.1 1.59 -0.14 -2.20 
1GS9 LYS 95 10.1 0.34 0.14 -3.12 
1GYM HIS 227 6.9 -0.64 -0.75 -0.68 
1GYM HIS 32 7.6 -2.94 -1.64 -1.44 
1GYM HIS 82 6.9 0.37 -0.94 -0.05 
1GYM HIS 92 5.4 0.55 0.13 0.37 
1HHO HIS 20 6.7 0.04 -0.06 -0.15 
1HHO HIS 45 7 -1.27 -1.5 -1.25 
1HHO HIS 50 7.5 -0.99 -0.69 -0.54 
1HHO HIS 72 6 1.23 0.83 1.03 
1HHO HIS 89 7.2 -2.02 -0.88 -0.90 
1HHO HIS 2 6.51 -1.33 -0.32 -0.40 
1HHO HIS 77 6.6 0.05 -0.06 0.30 
1HNG GLU 41 6.7 -1.34 -2.54 -1.94 
1HRC HIS 33 6.4 -0.86 0.17 -0.08 
1HRC LYS 79 9 1.70 1.47 -1.89 
1HV0 GLU 78 5 -0.85 0.64 -1.15 
1HV1 GLU 78 4.2 3.49 1.73 1.86 
1L54 LYS 102 6.5 -0.58 1.71 -2.29 
1L98 GLU 105 6 -1.62 -1.24 -2.08 
1LE2 LYS 143 9.4 0.87 -0.16 -2.83 
1LE2 LYS 146 9.9 0.33 -0.2 -3.32 
1LE2 LYS 157 10.9 -0.33 -0.23 -3.78 




1LE2 LYS 69 10.1 0.58 0.6 -2.90 
1LE2 LYS 72 10 0.55 0.34 -2.92 
1LE2 LYS 75 10 0.42 0.31 -2.69 
1LE2 LYS 95 10.2 0.25 0.21 -3.20 
1LZ1 HIS 78 7.12 -0.68 -0.65 -0.87 
1NFN LYS 143 9.5 0.85 0.4 -2.71 
1NFN LYS 146 9.2 1.11 0.45 -2.52 
1NFN LYS 157 11.1 -0.54 -0.53 -4.00 
1NFN LYS 69 10.4 0.41 0.26 -3.10 
1NFN LYS 72 10 0.69 0.64 -2.76 
1NFN LYS 75 10.1 0.88 0.1 -2.57 
1NFN LYS 95 10.1 0.29 0.24 -3.21 
1PGA LYS 10 11 -0.35 -0.11 -3.78 
1PGA GLU 15 4.4 -0.67 -0.41 -0.70 
1PGA GLU 19 3.7 0.28 0.27 0.01 
1PGA ASP 22 2.9 0.31 -0.52 -0.04 
1PGA GLU 27 4.5 -0.78 -1.09 -1.04 
1PGA LYS 28 10.9 0.31 -0.5 -3.47 
1PGA ASP 36 3.8 0.61 0.23 0.04 
1PGA ASP 40 4 0.03 -0.1 -0.42 
1PGA GLU 42 4.4 0.04 -0.02 -0.17 
1PGA ASP 46 3.6 0.31 -0.55 -0.10 
1PGA ASP 47 3.4 0.01 -0.61 -0.34 
1PGA GLU 56 4 0.51 0.45 -0.01 
1PNT HIS 66 8.29 -2.01 -1.74 -1.21 
1PNT HIS 72 9.19 -2.09 -2.47 -2.98 
1POH HIS 76 6 -0.86 0.18 0.32 
1PPF ASP 7 2.99 0.58 0.09 0.14 
1PPF GLU 10 4.1 0.00 0.09 -0.17 
1PPF LYS 13 9.9 0.50 0.93 -2.86 
1PPF GLU 19 3.2 0.50 0.68 0.21 
1PPF ASP 27 2.71 1.21 -0.22 0.31 
1PPF LYS 29 11.1 -0.64 -0.89 -3.94 
1PPF LYS 34 10.1 0.88 0.3 -2.65 
1PPF GLU 43 4.7 -0.29 -0.52 -0.57 
1PPF LYS 55 11.1 -0.59 -0.83 -4.09 
1RCA ASP 121 3.1 1.11 -0.31 0.20 
1RCA ASP 14 2 1.20 0 0.66 
1RCA ASP 38 3.1 0.75 0.12 0.12 
1RCA ASP 53 3.9 0.06 0.28 -0.24 
1RCA ASP 83 3.5 -0.24 -0.37 -0.53 
1RCA GLU 111 3.5 1.23 0.6 0.83 
1RCA GLU 2 2.8 0.92 0.47 0.37 
1RCA GLU 49 4.7 -0.35 -0.56 -0.67 
1RCA GLU 86 4.1 0.12 -0.06 -0.25 
1RCA GLU 9 4 0.55 0.08 -0.10 
1RCA HIS 105 6.7 0.30 -0.24 0.00 
1RCA HIS 119 6.1 1.17 0.23 0.06 




1RCA HIS 12 6.2 -1.03 -1.34 -0.68 
1RCA HIS 48 6 0.78 -1.07 -0.09 
1RGG ASP 1 3.44 0.67 0.72 0.28 
1RGG ASP 17 3.72 0.40 0.68 0.04 
1RGG ASP 25 4.87 -0.72 -0.46 -1.05 
1RGG ASP 33 2.39 0.47 1.58 -0.48 
1RGG ASP 79 7.37 -1.84 -2.17 -2.61 
1RGG ASP 84 3.01 0.34 -0.95 -0.29 
1RGG ASP 93 3.09 0.88 0.1 0.59 
1RGG GLU 14 5.02 0.13 -0.51 -0.36 
1RGG GLU 41 4.14 0.03 0.15 -0.14 
1RGG GLU 74 3.47 1.02 1.06 0.79 
1RGG GLU 78 3.13 1.69 1.31 0.99 
1RGG HIS 53 8.27 -1.00 -1.27 -0.60 
1RGG HIS 85 6.35 -0.18 0.07 0.21 
1XNB ASP 106 2.7 1.39 1.19 1.04 
1XNB ASP 11 2.5 1.09 0.35 0.54 
1XNB ASP 119 3.2 0.01 -0.32 -0.22 
1XNB ASP 121 3.6 0.27 0.4 -0.10 
1XNB ASP 4 3 0.35 -0.63 -0.17 
1XNB GLU 78 4.6 1.32 0.95 0.31 
1XNB HIS 156 6.5 -0.31 -0.62 -0.89 
1XWW HIS 157 7.72 -1.29 -0.36 -0.81 
1XWW HIS 66 8.22 -2.16 -2.09 -1.61 
1XWW HIS 69 6.4 -0.18 -0.47 -0.47 
1XWW HIS 72 9.18 -3.60 -2.45 -3.21 
1YMB HIS 113 5.4 -0.10 1.28 1.38 
1YMB HIS 116 6.6 -0.71 -0.64 -0.30 
1YMB HIS 119 6.4 -3.97 0.08 -0.14 
1YMB HIS 36 7.8 -1.66 -1.59 -1.00 
1YMB HIS 81 6.6 -0.13 -0.21 -0.14 
2CPL HIS 126 6.34 -0.74 -0.14 0.06 
2CPL HIS 70 5.84 0.52 -0.15 0.32 
2LZT LYS 1 10.6 -0.20 -0.26 -3.71 
2LZT GLU 7 2.73 1.02 1.08 0.90 
2LZT LYS 13 10.3 0.33 0.27 -3.03 
2LZT HIS 15 5.58 -0.42 0.29 0.16 
2LZT ASP 18 2.78 0.89 0.57 0.45 
2LZT LYS 33 10.4 0.40 -0.61 -3.07 
2LZT GLU 35 6.15 0.22 -1.66 -0.97 
2LZT ASP 48 3.4 -0.17 -1.17 -0.67 
2LZT ASP 52 3.67 0.19 0.18 0.02 
2LZT ASP 66 2 0.75 -0.25 -0.06 
2LZT ASP 87 2.84 0.46 0.26 0.14 
2LZT LYS 96 10.7 -0.74 -0.6 -3.94 
2LZT LYS 97 10.1 0.47 0.45 -2.83 
2LZT ASP 101 4.17 0.02 -0.46 -0.65 
2LZT LYS 116 10.2 0.03 -0.19 -3.48 




2LZT ASP 119 2.85 0.38 -0.26 -0.02 
2MB5 HIS 113 5.44 0.31 0.94 1.14 
2MB5 HIS 116 6.49 -0.21 -0.31 0.00 
2MB5 HIS 119 6.13 -1.69 -0.43 0.10 
2MB5 HIS 12 6.29 -0.17 0.17 0.33 
2MB5 HIS 48 5.25 0.95 0.93 1.17 
2MB5 HIS 81 6.68 -0.14 0.07 0.02 
2MB5 HIS 97 5.63 0.38 -0.32 -0.22 
2RN2 GLU 6 4.1 0.47 -0.4 -0.04 
2RN2 ASP 10 5.52 -1.24 -0.56 -1.39 
2RN2 GLU 32 3.5 -0.26 0.19 -0.36 
2RN2 GLU 48 4.2 0.03 -0.31 -0.22 
2RN2 GLU 57 3.67 -0.37 0.05 -0.47 
2RN2 GLU 61 4.03 -0.27 -0.57 -0.67 
2RN2 HIS 62 7 -0.25 0.2 0.06 
2RN2 GLU 64 4.47 -0.19 -0.71 -0.57 
2RN2 ASP 70 3.37 0.85 0.45 0.24 
2RN2 HIS 83 5.5 0.37 0.43 0.43 
2RN2 ASP 94 3.27 -0.02 -0.96 -0.56 
2RN2 ASP 102 2 2.14 0.81 1.18 
2RN2 ASP 108 3.55 0.46 -0.1 -0.07 
2RN2 HIS 114 5 0.25 0.24 1.93 
2RN2 GLU 119 4.47 -0.72 -0.4 -0.94 
2RN2 HIS 124 7.1 -1.25 -0.49 -0.35 
2RN2 HIS 127 7.9 -0.82 -0.32 -0.17 
2RN2 GLU 129 3.7 0.53 0.17 0.07 
2RN2 GLU 131 4.47 0.00 -0.08 -0.22 
2RN2 ASP 134 4.12 -0.67 0.39 -0.68 
2RN2 GLU 135 4.5 -0.13 -0.29 -0.34 
2RN2 GLU 147 4.23 0.08 0.1 -0.11 
2RN2 ASP 148 2 1.25 -0.65 0.26 
2RN2 GLU 154 4.35 -0.35 -0.42 -0.70 
2TGA ASP 102 1.4 1.34 3.29 1.23 
2TGA ASP 194 2.3 1.72 2.73 0.94 
2TGA HIS 40 4.6 1.23 1.63 2.45 
2TGA HIS 57 7.3 -1.19 -0.97 -0.20 
2TRX ASP 26 7.5 0.50 0 -1.84 
3EBX HIS 26 5.8 -0.32 -0.09 0.42 
3ICB LYS 1 10.6 0.54 0.09 -3.31 
3ICB LYS 7 11.35 -0.14 -0.84 -3.58 
3ICB LYS 12 11 0.75 -0.15 -3.13 
3ICB LYS 16 10.09 0.92 0.98 -2.64 
3ICB LYS 25 11.69 0.06 -0.65 -3.62 
3ICB LYS 29 10.99 0.29 -0.94 -3.21 
3ICB LYS 41 10.89 -0.25 -0.55 -3.84 
3ICB LYS 55 11.39 0.36 -0.77 -3.71 
3ICB LYS 71 10.72 -0.07 -0.26 -3.54 
3ICB LYS 72 10.97 -0.22 -0.4 -3.70 




3RN3 GLU 2 2.81 1.03 0.73 0.58 
3RN3 GLU 9 4 0.56 0.12 0.23 
3RN3 HIS 12 6.2 -0.37 -0.91 -0.67 
3RN3 ASP 14 2 0.62 -0.53 0.33 
3RN3 ASP 38 3.1 0.71 0.2 0.11 
3RN3 HIS 48 6 0.44 -0.84 -1.61 
3RN3 GLU 49 4.7 -0.36 -0.47 -0.66 
3RN3 ASP 53 3.9 0.05 0.31 -0.25 
3RN3 ASP 83 3.5 -0.39 -0.52 -0.62 
3RN3 GLU 86 4.1 -0.34 -0.21 -0.54 
3RN3 HIS 105 6.7 0.40 -0.32 -0.07 
3RN3 GLU 111 3.5 0.87 0.46 0.58 
3RN3 HIS 119 6.09 0.16 0.26 0.25 
3RN3 ASP 121 3.1 0.82 -0.1 -0.01 
3RNT HIS 27 7.3 -1.33 -0.2 0.07 
3RNT GLU 28 5.9 -0.96 -1.41 -1.38 
3RNT HIS 40 7.9 -0.86 -1.18 -0.72 
3RNT GLU 58 4.3 0.77 -0.16 0.15 
3RNT HIS 92 7.8 -0.93 -1.43 -0.78 
3SRN HIS 105 6.66 -0.13 -0.3 -0.22 
3SRN HIS 119 6.31 -0.08 0.03 -0.26 
3SRN HIS 12 5.85 -0.62 -0.24 -0.30 
3SSI HIS 106 6 -0.73 -0.52 -0.26 
4HHB HIS 112 7.6 -0.36 -0.8 -0.20 
4HHB HIS 72 6.6 0.24 0.37 0.73 
4HHB HIS 89 7.18 -0.68 -0.8 -0.46 
4HHB HIS 143 6.25 -0.67 -0.13 0.24 
4HHB HIS 77 6.75 -0.40 0.12 -0.01 
4PTI ASP 3 3.57 0.26 -0.04 -0.26 
4PTI GLU 7 3.89 0.17 0.44 -0.11 
4PTI LYS 15 10.43 0.02 -0.2 -3.63 
4PTI LYS 26 10.1 0.32 0.23 -3.27 
4PTI LYS 41 10.6 0.03 -0.11 -3.50 
4PTI LYS 46 9.87 0.50 0.43 -3.00 
4PTI GLU 49 4 0.16 0.17 -0.03 
4PTI ASP 50 3.18 -0.42 -0.12 -0.49 
5PNT HIS 157 7.49 -1.02 -0.83 -0.81 
5PNT HIS 66 7.67 -2.26 -1.04 -0.86 
5PNT HIS 72 9.23 -2.01 -2.17 -2.60 
6GST HIS 167 7.77 -0.74 -0.5 -0.28 
6GST HIS 83 5.18 0.61 1.06 1.72 
6GST HIS 84 7.08 -0.74 -0.74 -0.68 
 




Chapter 6  
Discussions and Future Directions 
The thesis focuses on protein-peptide interactions and more specifically, 
protein-PPII interactions. In this thesis, first I have helped to solve two crystal 
structures as well as applied MD simulation to study the mechanism why 
CLIP is abundant in DQ2.5. As the abundance of CLIP is connect to the 
editing process catalyzed by DM in MHCII proteins, in the next chapter, a 
pure computational MD study was applied on six systems to reveal the 
dynamic of peptide editing process. These two chapters focus on one example 
of protein-PPII interactions, in the following chapter, the characteristics of 
PPII-binding protein was generalized and applied to predict the PPII receptors. 
Another aspect that was tacked to reveal the protein-peptide interaction is the 
pKa prediction of ionizable residues. The pKa prediction could help to estimate 
the protonation state of those ionizable residues and hence understand protein 
functions. The conclusions and future directions of each topic are discussed in 
separate sections.  
6.1 3D structures of DQ2.5-CLIP complexes 
6.1.1 Summary 
In this section, the structures of DQ2.5 in complex with two CLIP peptides, 
namely CLIP1 and CLIP2 have been determined by X-ray crystallography. 
The analysis of crystal structures shows that DQ2.5 has an unusually large P4 
pocket and a positively charged peptide binding groove. These two features 
together promote preferential binding of CLIP2 over CLIP1. In addition, there 




is a α9-α22-α24-α31-β86-β90 hydrogen bond network which locates at the 
bottom of the peptide binding groove of DQ2.5. The hydrogen bond network 
spanning from the P1 to P4 pockets results in the relative immobility of 
hydrogen bond making residues. This network, as well as the deletion 
mutation at α53, may lead to the DM insensitivity of DQ2.5. Later, this 
hypothesis is proven by the MD simulations. The recent biochemical studies 
by other groups also support our hypothesis. In conclusion, diminished DM 
sensitivity is a reason for the CLIP-rich phenotype of DQ2.5. 
6.1.2 Suggestions and Future Directions 
In this study, we use an implication that the DQ2.5‒DM interaction is similar 
to DR–DM interaction, which is shown by the available crystal structure. 
However, as DQ2.5 structure has a deletion at α53. It could be possible that 
DQ2.5‒peptide‒DM structure at the interaction site is different from DR–
peptide-DM. DQ2.5 protein has been shown to be correlated with celiac 
disease and type 1 diabetes, and hence, understanding DQ2.5‒DM interaction 
could give some clues for understanding the disease mechanism as well as 
proposing specific treatments. We suggest that the DQ2.5‒DM structure 
should be solved in order to have an elaborate and accurate view of the 
DQ2.5‒DM interaction. 




6.2 The Molecular Mechanism behind the Peptide-
editing Process of MHCII by DM Catalyst: an MD 
study 
6.2.1 Summary 
In this study, we investigated the mechanism on six systems: model_5.5, 
model_6.5, DR–HA–DM, DR–DM, DR–HA and DR. The simulations 
revealed that model_5.5 and model_6.5 have fluctuation differences at the β2 
domain of DR. Both systems also have smaller conformational change with 
respect to the starting structure. The DR–HA–DM simulations showed the 
stabilization of DR β2 domain by interacting with the DM β2 domain. All 
three DR–DM complex in the presence of peptide presented the 
conformational change at the α69-75 region in DM. Although this DM α 
region is far from the DR–DM interaction site, it could be possible that the 
conformational change in that region could result in the long-range effect onto 
the DR–DM interaction. In this study, we also showed the stable close state of 
the peptide-free DR. The closing conformation is not observed in the presence 
of DM. This observation is consistent with the hypothesis that DM stabilizes 
the peptide-free DR. 
6.2.2 Suggestions and future directions 
In this study the change from the apo to the holo conformation has not been 
observed yet. The differences between the apo and the holo forms are at the 
peptide-binding site and β2 domains of DR/DM proteins. We suggest that the 
replica-exchange MD simulations, but not the standard MD simulations used 




in this study, in the interaction site could be used to enhance the sampling at 
that region. The MHCII proteins are polymorphic, and the MHCII–DM 
interaction could be fully understood if the simulations of the complexes 
between DM and all types of human MHCII proteins, namely DR, DQ and DP 
are extensively studied. Another suggestion is that the experimental studies on 
β2 domain of DR and α69-75 region of DM should get more attention. 
 
6.3 Prediction of PPII receptors  
6.3.1 Summary 
Protein-PPII interaction occurs in many signalling network, immune response 
etc. Finding the PPII receptors could elaborate the possible network of PPII 
peptide or proteins containing PPII peptides. In this study, we have shown the 
important features of the PPII-binding site. We also used those features to 
predict the PPII-binding site of a query protein. After applying the prediction 
protocol, on a non-redundant dataset of 17, 000 proteins, 125 possible PPII-
binding proteins have been detected. This PPII prediction program is 
comparable to the state-of the-art methods in predicting protein-peptide 
interactions. 
6.3.2 Suggestions and future directions 
In this study, we suggest 125 proteins that could be plausible PPII receptors. 
These data remain to be tested by experiments. Our assumption in this study is 
that the apo and the holo conformations of the PPII receptors are not 




significantly different. In other words, we simplified the protocol by using 
only the holo forms as templates. Both the apo and the holo conformations 
should be used for searching the PPII-binding sites. The apo forms could be 
generated by MD simulations.  
Our PPII prediction used the Trp residues as a requirement for PPII-binding 
sites. There are other PPII receptors, such as collagen-bind proteins or PDZ 
domain that do not have Trp. It could be possible to generalize the protocol by 
using any two donor residues as templates.  
In addition, similar protocol could be applied to other protein-bound peptide 
conformations such as α-helix. Particularly, the features for the α-helix binding 
proteins should be extracted from the known α-helix binding proteins. The 
CLICK structural alignment program could be used to compare a query 
structure with the template. Classification approaches, not limited to SVM 
could be applied to distinguish the binding/non-binding positions. The α 
peptide can also be built by Monte Carlo simulations to reduce the clashes 
between the template peptide and the query protein. 




The PPII prediction protocol focused only on the 
conformation of the protein and the PPII peptide. The 
sequences of either PPII or receptors were ignored. 
More attention should be paid to the sequence 
characteristics of the peptides, as it could be helpful 
for the design of a potential drug candidate. This 
could be a future research direction to be 
explored.6.4 pKa prediction of ionizable residues 
6.4.1 Summary 
From chapter two to chapter four, we have studied protein-peptide 
interactions. In chapter 3, the protein-peptide interactions are shown to be 
highly dependent on the protonation states of ionizable residues. In a broader 
context, the protein function is monitored by the pKa of all ionizable residues. 
And hence, in chapter five, we utilized two linear regression models in order 
to predict the pKa of ionizable residues. The first model used residue depth in 
describing the microenvironment. This model gives the RMSD of pKa 
prediction values of 1 pH unit in comparison with experimental values. The 
first model was also shown to complement with another state-of-the-art pKa 
prediction program, MMSCP. As a consequence, a meta-algorithm was 
applied to build the second model that improved the prediction to 0.7 pH unit 
RMSD. This study has been of benefit in studying the protein interactions with 
changing protonation states of ionizable residues, such as in the case of triad 
catalytic Ser-His-Asp motif or MHCII–DM interactions. The web-server of 
the first model is also freely available (http://mspc.bii.a-star.edu.sg/depth). 




6.4.2 Suggestion and future direction 
One major possible improvement in pKa prediction approach is the shift of pKa 
value in different pH conditions. Our pKa prediction implies that the 
protonation states of neighbourhood residues are typically oversimplified by 
using the protonation states of isolated residues at pH 7. The calculation 
should consider the pKa shift of ionizable residues that are surrounding the 
interested residue. In addition, we only predicted the pKa for ASP, GLU, HIS 
and LYS. It should be expanded to CYS, TYR and ARG. Another possible 
improvement in the pKa prediction approach is that in the case of HIS we only 
predicted whether the HIS is either in the protonated or deprotonated. In the 
deprotonated state, there are two possible conformations, either deprotonated 
at N
δ1
 or at N
ε2
. However, due to the paucity of experimental data, these 
predictions are currently not made as they are not testable.  
6.5 Conclusion remarks 
In this thesis, I have extensively investigated protein-peptide interactions, 
where the peptides have the PPII conformation. First, I helped to solve the 
crystal structures of DQ2.5 with two different CLIP peptides. Two 
specificities were suggested as the reasons why CLIP is retained in DQ2.5, but 
not DR1, namely, the deletion at α53 position in DQ2.5 and the hydrogen 
bond network from P1 to P4 pocket. The reason why DQ2.5 prefers to bind 
CLIP2 was proposed as DQ2.5 has a bigger P4 pocket than other MHCII 
homolog. And hence, CLIP2 peptide that has Met at P4 position prefers to 
bind DQ2.5. DQ2.5 is highly correlated with type 1 diabetes and celiac disease 




and hence, this study could contribute to the knowledge of these diseases and 
their treatments.  
As the peptide editing in MHCII is catalyzed by DM. We next performed MD 
simulations on six systems to address the following questions, (i) why DR–
DM interaction occurs only at pH 5.5 but not at pH 6.5, (ii) what are the 
important residues for the DR–DM interaction (iii) how these residues change 
from the apo to the holo conformations, (iv) how peptide releases from DR 
and (v) how DM stabilizes free-peptide DR. We revealed that the 
conformational change during DR–DM interaction happens not only at the α1 
and β1 domain, but also at the β2 domains. We also showed that without DM, 
peptide-free DR closed the peptide binding groove. This study deciphers the 
DR–DM interaction that is important for peptide exchange and hence immune 
response process. In other words, this study gives a broad overview of how our 
immune system response when the pathogens entry our body.  
These two studies above focus on the example of MHCII-peptide complexes. 
We expanded the knowledge on protein-PPII interactions by analyzing 
important features for the PPII-binding proteins. Several features, particularly, 
the number of hydrogen bonds, residue depth and entropy conservation were 
also shown to be important for the PPII-binding site. We then applied those 
requirements to predict the PPII receptors. The prediction of PPII receptors 
could be applied on studying the network of the PPII-peptide or protein 
containing the PPII conformation stretch. 
Last, chapter 3 shows in that the protein-peptide interactions highly depend on 
the pH condition. This pH condition monitors the protonation state of all 
ionizable residues, and hence, we conducted pKa prediction protocol. Two 




models were built. One used linear regression of residue depth, ASA, number 
of hydrogen bond and electrostatic. The second is the meta-algorithm of the 
first model and its complementary method, MMSCP. The later model showed 
the RMSD of only 0.7 pH units. Assigning protonation state of ionizable 
residues is important to understand the protein functions. And hence, this fast 
and accurate pKa prediction tool could give biologist some ideas about the 
charge states of ionizable residues, as well as the total net charge of the 
protein, and hence, the protein functions. 
In summary, using computational approaches the protein-peptide interactions 
have been tackled broadly. In each study, we have addressed several important 
problems. We believe that this work makes a positive contribution to the 
knowledge of protein-peptide interactions. 
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